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1a. RGS proteins modulate cellular signaling. 
 
G Protein-Coupled Receptors (GPCRs) are a family of over 800 proteins that 
contain seven transmembrane regions (Pierce, et al. 2002). When activated by an agonist, 
such as a hormone, a neurotransmitter, a drug, or a photon of light, a GPCR stimulates 
exchange of GTP for GDP on the Gα subunit of the heterotrimeric G protein, which then 
undergoes an activating conformational change that allows it and its associated βγ subunit 
to interact with effector proteins (Figure 1.1) (Hepler. 1999). This can result in a number 
of downstream signaling events that can cause changes in membrane polarization, 
changes in neurotransmitter or hormone release, gene transcription or other cellular 
events (Pierce, et al. 2002). The Gα subunit inactivates itself by hydrolyzing GTP to GDP 
and this allows reassociation with Gβγ and the receptor. Unlike GTPase accelerating 
proteins (GAPs) for small G-Proteins, regulators of G protein signaling (RGS) proteins 
bind to the activated Gα protein and stabilize the transition state for GTP hydrolysis 
without directly interacting with the nucleotide (Tesmer, et al. 1997, Berman, et al. 
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1996a). This accelerates GTP hydrolysis and inactivation of the G-protein, and inhibits 
cell responses to GPCR signaling. 
In 1982, Chan and Otte found a protein in Saccharomyces cerevisiae, Sst2, that 
when mutated resulted in increased sensitivity to pheromone responses through a yeast 
GPCR using a growth arrest read-out (Chan & Otte. 1982). It was then found that Sst2 
was not affecting Gpa1 (the yeast Gα protein) stability or anything downstream of Gpa1 
(Dohlman, et al. 1995). Another study showed that overexpression of Sst2 caused 
decreased pheromone signaling and that Sst2 could be isolated in complex with Gpa1, 
thus demonstrating that Sst2 regulates signaling by acting on the G-protein. It was 
noticed that Sst2 had homology with other mammalian proteins, some of which were 
known to be GAPs (Dohlman, et al. 1996). Soon new RGS proteins were identified, and 
it was found that putting these proteins into yeast blunted signal transduction and reduced 
pheromone sensitivity in yeast lacking Sst2 (Druey, et al. 1996). Hence Sst2 became the 
founding member of a family of RGS proteins. At the same time, Egl 10, the C. elegans 
RGS protein (Koelle & Horvitz 1996), and G-alpha interacting protein (GAIP) (DeVries, 
et al. 1995) were discovered independently. 









Figure 1.1: The G Protein cycle. When activated by an agonist, a GPCR 
stimulates exchange of GTP for GDP on the Gα subunit of the heterotrimeric G protein, 
which results in an activating conformational change allowing both the α and the βγ 
subunits to interact with effector proteins. The Gα subunit inactivates itself by 
hydrolyzing GTP to GDP and this allows reassociation with Gβγ and the receptor. RGS 
proteins accelerate GTP hydrolysis and inactivation of the G protein. 
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The RGS proteins are divided into several families. There have been over 30 
RGS proteins identified (Abramow-Newerly, et al. 2006), which are divided into families 
based on the homology of the 120 amino acid RGS domain as well as the presence or 
absence of other domains (Figure 1.2) (Hepler. 1999). Members of the R4 (containing 
RGS1, RGS2, RGS3, RGS4, RGS8, RGS13, RGS16 and RGS18) and the RZ (containing 
RGS19 (also called GAIP), RGS20 (also called RGSZ1) and RGS17 (also called 
RGSZ2)) families primarily contain the RGS domain, however the R4 family also has a 
short amphipathic N-terminus (Bernstein, et al. 2000, Bernstein, et al. 2004) that plays a 
role in membrane targeting and/or receptor specificity (Bernstein, et al. 2000, Bernstein, 
et al. 2004, Gu, et al. 2007a). On the other hand, RZ family members contain a string of 
cysteines in the N-terminus that can be palmitoylated (Hiol, et al. 2003, Nunn, et al. 
2006) (Figure 1.2). Hence the N-termini of both families are important for membrane 
targeting. 
Other RGS families have accessory domains. RGS6, RGS7, RGS9 and RGS11 
are R7 family members and have a Dishevelled/EGL-10/Pleckstrin (DEP) domain which 
is thought to mediate RGS-receptor interactions (Ballon, et al. 2006, Chen & Hamm. 
2006), and a Gγ-like (GGL) domain which binds Gβ5 (Witherow & Slepak. 2003).  
RGS9 has two splice variants, with RGS9-2 having an extra 191 amino acids in the C-
terminus (Rahman, et al. 1999). It is interesting that the different splice variants have 
strikingly distinct expression patterns: RGS9-1 is only expressed in the retina, while 
RGS9-2 is expressed in the brain, mostly in the striatum, but not the retina (Rahman, et 
al. 1999). The R12 family includes RGS10, RGS12 and RGS14 and these family 
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members have PSD95, Dlg and Z0-1/2 (PDZ) domains involved in protein-protein 
interactions (Snow, et al. 2002), phosphotyrosine-binding domains (PTB), Ras-binding 
(RBD) domains and GoLoco motifs which are guanine-nucleotide dissociation inhibitors 
(GDIs). The fact that both GDI and GAP domains for Gαi exist on the same protein may 
have interesting implications for the function of R12 family members. The significance 
of this has yet to be fully evaluated. Members of the E/RA family, Axin and Conductin, 
contain a glycogen synthase kinase3-β binding (GSK3β) domain, a β-catenin binding 
(Cat) site, a protein phosphatase 2A homology region (PP2A), and a dimerization (DIX) 
domain (Hollinger & Hepler. 2004). Other proteins that contain RGS homology (RH, 
rather than true RGS) domains include members of the G protein receptor kinase (GRK), 
sorting nexin (SNX), axin, and Rho guanine-nucleotide exchange factor (RhoGEF) 
families. Non-RGS domains in RGS proteins regulate other steps in the G Protein cycle 
(with GDI and GEF domains), mediate protein-protein interactions, post-translational 
modifications, and cellular localization. This can result in specific and complex actions of 
these proteins. It can be speculated that multiple actions of a single protein could allow 
for targeted effects and pathway integration.  







Figure 1.2: RGS families. From (Neubig & Siderovski. 2002). Prototypical RGS 
members are on the left and family designation is on the right. RGS families are 
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 Structural insights have been gained from X-ray crystalograph. Shortly after 
the discovery of RGS proteins, Tesmer et al. solved the first RGS crystal structure in 
1997. This structure of RGS4 bound to AlF4-activated Gαi1 has been very useful for 
understanding how RGS proteins interact with Gα subunits to stabilize the transition state 
of GTP hydrolysis without directly interacting with the nucleotide. The RGS protein 
contacts the three switch regions of the Gα subunit that mediate the binding to and 
hydrolysis of the GTP. Since the elucidation of this structure, several other RGS 
structures, both NMR and X-ray, have been determined. These include RGS proteins 
alone or in complex with associated proteins for 18 different RGS proteins in 7 families 
(Cheever, et al. 2008a, Cheever, et al. 2008b, Chen, et al. 2001, Chen, et al. 2003, Chen, 
et al. 2005, Fedorov, et al. 2007, Higman, et al. 2006a, Higman, et al. 2006b, Higman, et 
al. 2006c, Lodowski, et al. 2005, Lodowski, et al. 2006, Longenecker, et al. 2001, Moy, 
et al. 1999, Moy, et al. 2000, Rhee, et al. 2006, Slep, et al. 2001, Slep, et al. 2008, 
Soundararajan, et al. 2008, Spink, et al. 2000, Sterne-Marr, et al. 2003, Tesmer, et al. 
1997, Tesmer, et al. 2005, de Alba, et al. 1999).   









Figure 1.3: Structure of RGS4 bound to Gαi1-AlF4-. From (Tesmer et al. 1997). A) The 
RGS protein is on top and is colored, while Gαi1 is on bottom in grey. The three switch 
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RGS proteins have G Protein selectivity. There are 23 Gα proteins divided into 
four families: Gαi, Gαs, Gαq, and Gα12 based on amino acid homology as well as 
functional similarities (Nurnberg, et al. 1995). Among other things, the Gαi family 
inhibits adenylyl cyclase (AC) activity while Gαs stimulates AC. One of the many 
functions of the Gαq family is its involvement in calcium mobilization, and the Gα12 
family activates small G-proteins (Neves, et al. 2002). By selectively regulating G-
proteins, RGS proteins can selectively regulate different signaling pathways (Table 1.1). 
Thus, although there is significant overlap, there is some G protein selectivity with RGS 
proteins. Since many GPCRs can activate more then one Gα subunit (Kenakin. 2007), 
one could speculate that this selectivity may be physiologically useful for selectively 
modulating one pathway over another.  









RGS family Gα subunits Reference 
RZ Gαi/o/z, Gαq De Vries, et al. 1995, Berman, et al. 1996b, 
Hepler, et al. 1997, Wang, et al. 1998 
R4 Gαi/o, Gαq Berman, et al. 1996b, Hepler, et al. 1997, 
Heximer, et al. 1999 
R7 Gαi/o (Hooks, et al. 2003, Lan, et al. 2000 
R12 Gαi/o (Hooks, et al. 2003, 
RA ND  
GEF Gα12/13 Hains, et al. 2004 
SNX maybe Gαs   Zheng, et al. 2001 
 
 
Table 1.1: Table of RGS-Gα selectivity. Different RGS families will act as GAPs for 






 11   
RGS proteins also have receptor selectivity. Even more so than with G protein 
selectivity, receptor selectivity can make RGS proteins very targeted and selective 
signaling modulators. There are many examples in the literature of RGS-receptor 
selectivity, but there is still a lot to learn about which RGSs are involved in which 
pathways.  
The muscarinic receptors have been the subject of multiple selectivity studies. 
RGS1, RGS3, RGS4 and RGS16 have been found to selectively regulate signaling by 
muscarinic receptors over cholecystokinin (for RGS1, RGS4, and RGS16) bombesin (for 
RGS4) or angiotensin AT1a receptors (for RGS3) (Wang, et al. 2002, Xu, et al. 1999). 
RGS3 has been shown to mediate both M2 and M3 muscarinic receptor signaling, while 
RGS2, RGS4, RGS5 and RGS16 have been shown to regulate M2 but not M3 signaling 
(Anger, et al. 2007). This is not supported by biochemical data showing that RGS2 
directly interacts with the M3 but not the M2 third intercellular loop (Bernstein, et al. 
2004). Not all RGS proteins can regulate muscarinic signaling. It has been shown that 
RGS5 and RGS9 fail to regulate muscarinic signaling (through non-selective muscarinic 
receptor activation or M2-selective activation respectively) but inhibit angiotensin- or D2-
mediated signaling respectively (Cabrera-Vera, et al. 2004, Wang, et al. 2002). This is in 
contrast to RGS8, which can regulate signaling by both D2 and M4 receptors, but not by 
adenosine receptors (Benians, et al. 2005). 
RGS selectivity is also seen with the opioid receptors. Morphine induces pigment 
aggregation in Xenopus melanophore cells. Overexpression of RGS2 but not RGS1, 
RGS3 or RGS4 caused a rightward shift in the morphine dose-response curve in this 
system (Potenza, et al. 1999). In COS-7 cells, RGS19/GAIP is selective for the 
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nociceptin receptor over the mu, delta or kappa opioid receptors (MOR, DOR or KOR) 
(Xie, et al. 2005). RGS selectivity is not limited to the above systems. RGS proteins 
regulate adrenaline activated α2aAR-Gαo fusion protein GTPase activity with the 
following order of potency: RGS16>RGS1>RGS19/GAIP (Hoffmann, et al. 2001). In 
another study, RGS4, RGS10 and RGS20/RGSZ1 were found to inhibit 5-
hydroxytryptamine (5-HT or serotonin) 1A receptor but not dopamine D2 receptor-
mediated signaling (Ghavami, et al. 2004). And finally, RGS1, RGS2, RGS3, and RGS4 
inhibit AT1 receptor signaling, whereas only RGS3 and to a lesser extent RGS4, inhibit 
endothelin-1 receptor signaling (Cho, et al. 2003).  
There is a lot of information regarding which RGS proteins can regulate which 
receptors in expression systems, however very few are supported with direct biochemical 
evaluation. There is also a great need for further evaluation of which RGS proteins 
regulate which signaling pathways in endogenous systems. There are limited examples of 
this, which will be discussed below in regard to receptor interactions and in regard to 
pathophysiology. 
 
Receptor selectivity can be achieved through direct binding of RGS proteins to 
receptors or through indirect interactions via scaffolds. There are examples of both 
methods in the literature. In some cases, the scaffolds mediate receptor interactions, or 
they can regulate cellular localization or stability of the RGS. Examples are given in 
Table 1.2.  
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RGS Scaffold Receptor Reference 
RGS2 Direct binding M1, α1αAR, β2AR Bernstein, et al. 2004, Hague, 
et al. 2005, Roy, et al. 2006 












D2 Jeanneteau, et al. 2004 
RGS9 ND. DEP 
domain required 
D2 Kovoor, et al. 2005 






Spinophilin αAR (in the case of 
RGS2 and RGS4) 






Neurabin Does NOT bind 
α1bAR, D2, M3, 
cholecystokinin 
receptors 
Wang, et al. 2007b 
RGS9 R9 anchoring 
protein (R9AP)  
Necessary for RGS9 
stability and activity 
Hu, et al. 2003a, Hu & 
Wensel. 2002, Keresztes, et 
al. 2004,  
R7 family Gβ5 Necessary for R7 
family stability and 
activity 
Cabrera, et al. 1998, Chen, et 
al. 2003, Kovoor, et al. 2000, 
Makino, et al. 1999, Snow, et 
al. 1998, Song, et al. 2007 
R7 family R7 binding 
protein (R7BP) 
Lipid rafts, also 
necessary for stability 
and function 
Nini, et al. 2007, Anderson, et 
al. 2007, Drenan, et al. 2005, 
Drenan, et al. 2006, 
Martemyanov, et al. 2005 
RGS9 α actinin NMDA Bouhamdan, et al. 2006 
 
Table 1.2: RGS proteins regulate GPCRs through direct interactions or through scaffolds. 
Examples of RGS proteins regulating or binding to receptors are shown. ND: not 
determined. 
 
















directly binds Gαs 
and AC 
Chatterjee, et al. 1997, Ghavami, 
et al. 2004, Johnson & Druey. 
2002, Roy, et al. 2003, Salim, et 
al. 2003, Scheschonka, et al. 
2000, Sinnarajah, et al. 2001, 
Tseng & Zhang. 1998, Ko, et al. 









GIRK RGSs mediate the 
kinetics of channel 
opening and closing 
as well as basal 
currents. RGS4 binds 
the channel directly. 
Doupnik, et al. 1997, Herlitze, et 
al. 1999, Inanobe, et al. 2001, 
Saitoh, et al. 1997, Saitoh, et al. 
1999, Keren-Raifman, et al. 2001, 







RGSs mediate the 
kinetics of channel 
opening and closing. 
RGS12 binds the 
channel directly. 
Jeong & Ikeda. 1998, Jeong & 
Ikeda. 2000, Mark, et al. 2000, 
Melliti, et al. 2001, Schiff, et al. 
2000, Richman, et al. 2005 
RGS9 phosphodiesterase 
γ (PDEγ) 
PDEγ increases the 
affinity of Gαt for 
RGS9. Gαt activates 
PDEγ 





PLCβ RGSs inhibit PLCβ.  Cunningham, et al. 2001, Hepler, 
et al. 1997, Heximer, et al. 1997, 
Saugstad, et al. 1998 
 
Table 1.3: RGS proteins regulate effector proteins. Examples are shown of RGS proteins 
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RGS proteins can directly interact with effectors to mediate GPCR signaling.  
In addition to regulating G protein signaling by acting as a GAP for Gα subunits, RGS 
proteins can regulate effector activity. See Table 1.3 for details. 
  
RGS proteins may be regulated by phospholipids and calmodulin. 
Phosphatidic acid binds to the RGS4 N-terminus and inhibits its GAP activity (Ouyang, 
et al. 2003, Tu & Wilkie. 2004). Phosphatidylinositol-3,4,5,-trisphosphate (PIP3) inhibits 
the modulatory capacity of RGS4 on GIRK currents in myocytes, but is reversed by 
direct binding of Ca2+/calmodulin (CAM) to RGS4 (Popov, et al. 2000, Ishii, et al. 2002). 
Both PIP3 and CAM were shown to compete for the same positively charged site on the 
RGS domain, which is distinct from the Gα binding site and the phosphatidic acid 
binding site (Ishii, et al. 2005a, Tu & Wilkie. 2004). It has been suggested that 
competition between CAM and PIP3 could result in the oscillatory Ca2+ signaling seen in 
pancreatic acinar cells (Luo, et al. 2001). According to the suggested model, PIP3 
inhibition of RGS4 would prevent inhibition of PLCβ. This would lead to increased Ca2+ 
levels which would lead to increased Ca2+/CAM interaction with RGS4, thus preventing 
PIP3 inhibition and completing the cycle (Abramow-Newerly, et al. 2006). This model is 
supported by the fact that a GAP deficient mutant of RGS4 still binds CAM and can 
prevent GIRK channel relaxation caused by Ca2+ mediated hyperpolarization in myocytes 
(Ishii, et al. 2001). 
 
RGS-insensitive Gα  proteins are useful tools for understanding endogenous 
RGS function. DiBello et al, using a yeast model, found a mutation in Gpa1 that 
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phenocopied Sst2 null yeast (DiBello, et al. 1998). It was later found that the homologous 
mutant in Gαi1 (G183S) and Gαo (G184S) abolished RGS GAP activity and markedly 
decreased RGS affinity for the G-proteins (Lan, et al. 1998). RGS-insensitive mutants of 
Gα subunits represent powerful tools for studying the endogenous RGS function without 
the need for overexpressing RGS proteins (although G-proteins with the mutation need to 
be expressed). It is also a good tool for understanding global RGS action in a system 
where the individual RGSs responsible are not known and possibly redundant. The 
identity of the G protein responsible for an effect can also be investigated. This system 
has been used to show that endogenous RGS proteins regulate norepinephrine inhibition 
of N-type calcium channels in rat sympathetic neurons (Jeong & Ikeda. 2000), adenosine-
induced presynaptic inhibition in hippocampal neurons through Gαo (Chen & Lambert. 
2000), dopamine-mediated GTPγS binding, agonist-mediated Ca2+ responses in CHO 
cells expressing the D2S receptor (Boutet-Robinet, et al. 2003), lysophosphatidic acid-
mediated inhibition of AC in ovarian cancer cells (Hurst, et al. 2008) and GABA(B) 
receptor-dependent desensitization of GIRK currents in human embryonic kidney (HEK) 
cells (Mutneja, et al. 2005).  
 This system has been used to measure the effects of RGS proteins in modulating 
MOR-mediated signaling in C6 cells overexpressing both the receptor and RGS-sensitive 
or RGS-insensitive Gαo. Pertussis toxin (PTX, which selectively inactivates Gαi/o)-
insensitive mutants of Gαo were used to eliminate the contributions of endogenous G 
proteins. Using this system, the contribution of that endogenous RGS proteins to regulate 
MOR-mediated AC inhibition and mitogen-activated protein kinase (MAPK) pathway 
activation were revealed (Clark, et al. 2003). Endogenous RGSs were also shown to 
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regulate AC supersensitization, which accompanies withdrawal of agonist treatment 
(Clark, et al. 2004) and MOR desensitization and leads to the development of tolerance 
(Clark & Traynor. 2005). Thus RGS proteins are involved in more than simply acute Gαo 
signal transduction. They can also regulate the effects of chronic agonist treatment and 
may be important in drug dependence, tolerance and withdrawal.  
 The RGS-insensitive mutations have been used in embryonic stem (ES) cells as 
well. A1 and M2 bradycardic responses were increased in mouse ES cells expressing the 
Gαo RGS-insensitive mutant instead of wild type Gαo at endogenous levels. Whereas 
only M2 responses were enhanced in the Gαi2 RGS-insensitive ES cell line (Fu, et al. 
2006). This shows both receptor and Gα selectivity of endogenous RGS proteins.    
 
1b. RGS proteins in pathophysiology 
 
RGS proteins are important in cardiovascular signaling. At least 15 different 
RGS proteins have been shown to be expressed at the mRNA level in the heart with 
expression levels varying with disease state and developmental stage (Doupnik, et al. 
2001, Kardestuncer, et al. 1998, Mittmann, et al. 2002).  Functional data are lacking for 
many of the RGS proteins, but the following outlines the importance of some of the more 
studied RGS proteins in regulating cardiovascular function.  
Hypertension. Hypertension is estimated to affect more then 72 million people in 
the US alone, and is a factor for the development of more serious heart disease 
(Rosamond, et al. 2008). Hypertension is unique in that it is perhaps the only disease for 
which such a strong connection to a single RGS (RGS2) has been demonstrated to date; 
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there is data on the genetic, cellular and animal levels in both mice and in humans for 
RGS2 involvement in blood pressure regulation. Compared to normotensive patients, 
RGS2 mRNA is lower in the peripheral blood mononuclear cells (PBM). Interestingly, 
there is an increased incidence of a C1114G polymorphism, and there is increased AT II 
stimulated calcium signaling and ERK activation in fibroblasts from hypertensive 
patients (Semplicini, et al. 2006). Other RGS2 polymorphisms have also been associated 
with hypertension in humans (Riddle, et al. 2006, Yang, et al. 2005) with one producing a 
mutant protein that has decreased expression and function (Bodenstein, et al. 2007). 
Taken together, these data support a strong role of RGS2 in the regulation of peripheral 
blood pressure. 
Studies in mice have been performed to try to elucidate the mechanism of these 
effects. The angiotensin receptor is Gαq-coupled and is activated by angiotensin II 
(AngII), a potent vasoconstrictor. AngII increases RGS2 expression through a 
phospholipase A2-dependent mechanism in vascular smooth muscle cells, which may be 
a negative feedback mechanism (Grant, et al. 2000, Li, et al. 2005, Xie, et al. 2007). 
Increased angiotensin signaling is thought to be responsible for the hypertensive 
phenotype seen in the RGS2-deficient mice as this phenotype can be reversed with AT1 
antagonists (Heximer, et al. 2003) and RGS2-deficient mice are hyper-responsive to 
AngII (Hercule, et al. 2007). In addition to the hypertension seen in the RGS2 knock-out 
mice, decreased RGS2 mRNA has been associated with hypertension in rats (Grayson, et 
al. 2007). 
RGS2 is also involved in the nitric oxide (NO)-stimulated cGMP pathway, which 
mediates the regulation of blood pressure. cGMP-activated protein kinase G (PKG) can 
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phosphorylate RGS2 and enhance RGS2 GAP activity. It also increases membrane 
localization, inhibition of thrombin receptor protease-activated receptor-1 signaling 
(Tang, et al. 2003) and RGS2 protein stability (Osei-Owusu, et al. 2007). It has also been 
found that RGS2 deficient mice are less sensitive to the vasodilating effects of the NO 
donor sodium nitroprusside (Sun, et al. 2005), suggesting that RGS2 mediates the 
vasodilating effects of NO.   
These data support the notion that decreased RGS2 function (with knock-out in 
mice or with human polymorphisms) causes hypertension through ablating the 
endogenous NO signaling. Increased angiotensin signaling also plays a role. Whether or 
not there is a relationship between the increased AngII signaling and the decreased NO-
mediated vasodilation is unclear, but there has been some suggestion that AngII can 
regulate endothelial nitric oxide synthase (Hennington, et al. 1998, Li, et al. 2007, 
Nakashima, et al. 2006, Ritter, et al. 2003, Suzuki, et al. 2006). 
In contrast to what is seen with RGS2, RGS5-deficient mice have hypotension. 
These mice have dilated aortas and increased signaling through spingosine 1 phosphate or 
in response to sodium nitroprusside. This suggests that RGS5 could be a potential anti-
hypertension target (Cho, et al. 2008). A three gene region of chromosome 1 that includes 
RGS5 has been associated with hypertension in humans (Chang, et al. 2007). In a cDNA 
screen, RGS5 was found to be upregulated in stroke-prone hypertensive rats compared to 
wild type (Kirsch, et al. 2001). RGS5 has been shown to be expressed in arteries but not 
veins (Adams, et al. 2000, Li, et al. 2004), and atrial expression is increased in mice 
overexpressing the β2AR (Jean-Baptiste, et al. 2005). 
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Cardiac Hypertrophy. Cardiac hypertrophy is a compensatory mechanism by 
which the heart increases size in an attempt to handle increased stress. Depending on the 
stress, this response may be beneficial or it could be detrimental and over time lead to 
heart failure. Many forms of hypertrophy result in increased expression of embryonic 
genes, and this has been used as an indicator of clinical severity, as well as an 
experimental read-out (Hunter & Chien. 1999).  
Changes in RGS levels have been observed in models of cardiac hypertrophy. 
RGS2 expression is upregulated by phenylephrine treatment (Gan, et al. 2005, Zou, et al. 
2006) and also by adenovirus containing a constitutively active Gαq (Q209L) in cultured 
myocytes (Hao, et al. 2006). In the phenylephrine model, RGS2 upregulation is blocked 
by adenosine receptor agonists, which are known to prevent hypertrophy (Gan, et al. 
2005). It has also been shown that RGS3 and RGS4 mRNA levels are increased in 
pulmonary artery-banded mice and also in growth factor-treated cultured myocytes 
(Zhang, et al. 1998). Aortic RGS2, RGS4 and RGS5 expression in an aortic banding 
model of hypertrophy was found to vary over time (Wang, et al. 2007a).  
Compensatory changes in RGS expression are suggestive of their role in the 
development of cardiac hypertrophy, but it does not prove that there is a role, or reveal 
the mechanism. To address these questions, recombinant RGSs can be introduced to 
myocytes or mice. Adenovirus overexpression of RGS2 protects cells from increased size 
and fetal gene expression by phenylephrine (Zou, et al. 2006) while decreases in RGS2 
expression with interfering RNA exacerbated hypertrophy in myocytes (Zhang, et al. 
2006). RGS4 overexpression blocked phenylephrine and endothelin induction of fetal 
genes and cell growth in isolated myocytes (Tamirisa, et al. 1999), reduced transaortic 
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constriction-induced hypertrophy which increased mortality in mice (Rogers, et al. 1999), 
prevented hypertrophy in Gαq overexpressing mice (Rogers, et al. 2001), and prevented 
hypertrophy in a transcription factor overexpression model (Harris, et al. 2004). Thus it 
appears that RGS4 blocks many forms of hypertrophy, both beneficial and detrimental. 
Gαi2 RGS-insensitive mutant knock-in. Mice that express the RGS-insensitive 
mutation of Gαi2 instead of the wild type protein develop cardiac hypertrophy (Huang, et 
al. 2006), consistent with other models described above. Studies performed in isolated 
perfused hearts from these mice confirmed what was observed in ES cells, where the 
mutation increases sensitivity to carbachol-mediated bradycardia. It was also found that 
these isolated hearts were more sensitive to carbachol-induced arrhythmias (Fu, et al. 
2007), consistent with the notion that RGS proteins may tightly regulate muscarinic 
signaling, as mentioned previously.  
 
RGS proteins are important in neurological disease. There is an extensive 
literature describing the roles of RGS proteins in neuronal function and disease. Several 
RGS proteins have been shown to be expressed in the brain, and in many cases they 
display very distinct expression patterns (Gold, et al. 1997, Grafstein-Dunn, et al. 2001, 
Ingi & Aoki. 2002, Krumins, et al. 2004).  
Psychosis. Schizophrenia is characterized by delusions, hallucinations, social 
withdrawal, attention and cognitive defects and is treated with drugs that antagonize the 
D2, serotonin, and other receptors (Hardman & Limbird. 2001). Several groups have 
found an association between RGS4 polymorphisms and schizophrenia (Bakker, et al. 
2007, Chen, et al. 2004, Chowdari, et al. 2002, Levitt, et al. 2006, Li & He. 2006, Morris, 
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et al. 2004, Williams, et al. 2004, Winantea, et al. 2006) while other studies have failed to 
detect an association (Guo, et al. 2006, Ishiguro, et al. 2007, Puri, et al. 2007, Rizig, et al. 
2006). Although it is not clear whether RGS4 is associated with the development of 
schizophrenia, recent evidence suggests that RGS2 and RGS5 variants may be associated 
with the severity of the disease in affected individuals (Campbell, et al. 2008). Similarly, 
allelic variations in RGS4 have been shown to influence brain development in humans, 
which may impact predisposition for psychosis (Buckholtz, et al. 2007). RGS4 
polymorphisms have also been shown to be associated with bipolar disorder in humans 
(Cordeiro, et al. 2005). 
To study the effects of RGS4 on signaling in schizophrenia, Gu et al did 
electrophysiology on pyramidal neurons from the prefrontal cortex (PFC) from rats. 
Application of an RGS specific antibody in the patch clamp pipette increased 5-HT1A–
but not D4-mediated inhibition of NMDA currents. These data suggest that RGS4 may 
protect against NMDA hypofunction, which is associated with schizophrenia (Gu, et al. 
2007b).  
RGS proteins not only play a role in the manifestation and severity of psychosis, 
but can also influence responses to antipsychotic drugs. Mice lacking RGS9 experience 
drug-induced dyskinesia when given quinpirole (a D2-like selective agonist) after 
dopamine (DA) depletion with reserpine (Kovoor, et al. 2005). This is consistent with the 
DA supersensitivity and increased D2 high affinity states seen in schizophrenia (Seeman, 
et al. 2006). Also, RGS2 polymorphisms in human are associated with worsening of 
parkinsonian symptoms from antipsychotic treatment (Greenbaum, et al. 2007).  
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RGSs have also been implicated in other neurological abnormalities. Mice lacking 
RGS2 have increased anxiety and decreased male aggression compared to wild type 
mice. It has been suggested that these behaviors may be due to the decreased dendritic 
spine density observed in the hippocampal CA1 neurons and decreased electrical activity 
of these neurons. Thus it has been suggested that RGS2 plays a role in the proper 
development of these neurons (Oliveira-Dos-Santos, et al. 2000).  
Neurodegenerative diseases. Parkinson’s Disease (PD) is caused by loss of DA 
neurons innervating the striatum. This is accompanied by increased acetylcholine (ACh) 
levels, and results in motor symptoms. The increase in ACh is thought to be due to a loss 
of DA activation of inhibitory D2 receptors on ACh releasing neurons and subsequent 
inhibition of Cav2 Ca2+ channels leading to increased ACh release. However, Ding et al 
suggests that it is actually M4 autoreceptors regulated by RGS4, which cause an increase 
in ACh release. They show with electrophysiology studies in isolated cholinergic 
interneurons from 6-hydroxydopamine (6-OHDA which selectively ablates DA neurons) 
lesioned, reserpine-treated and untreated mice that DA depletion decreased oxotremorine-
M (a muscarinic agonist) but not quinpirole-mediated Ca2+ currents. DA depletion also 
leads to increased RGS4 expression in these cells and inclusion of RGS4 in the patch 
clamp pipette mimicked the effect of DA depletion in cells from untreated mice (Ding, et 
al. 2006). These data suggest that RGS4 may inhibit the inhibitory M4 receptor. Thus 
RGS4 activity in the DA depletion model results in increased Ca2+ channel activity, 
increased ACh release, and exacerbated motor symptoms. These data also support the 
notion that RGS4 could be a therapeutic target for the treatment of Parkinson’s disease.  
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Like PD, AD (Alzheimer’s Disease) is a neurodegenerative disease that is 
associated with a progressive and premature onset of dementia, eventually leading to 
fatality. This correlates with the appearance of β-amyloid plaques, neurofibrillary tangles 
and loss of neurons (Masters, et al. 2006). In studies performed on brains from deceased 
AD and normal age matched patients, RGS4 and Gαq protein levels were found to be 
lower in the parietal cortex (53 and 40% respectively) while membrane-bound protein 
levels were unchanged. These changes also correlated with changes in carbachol binding 
(Muma, et al. 2003). 
Morphine treatment of pain. Morphine and other opiates are of great clinical 
importance for the treatment of pain. However, their use is limited due to the 
development of tolerance and their related abuse liability (Rozenfeld, et al. 2007). 
Perhaps the most impressive illustration of the importance of RGS proteins in opioid 
receptor signaling is the phenotype of the RGS9-deficient mice. These mice have 
increased morphine reward, analgesia, delayed tolerance and exacerbated dependence 
and withdrawal symptoms (Rodriguez-Munoz, et al. 2007b).  
The Garzon lab has several studies on the effects of antisense 
oligodeoxynucleotides (ODN) of RGSs in mice. They found that knock-down of RGS9 
but not RGS2 increased the potency and duration of action of morphine analgesia 
(Garzon, et al. 2001) due to regulation of the MOR but not the DOR (Sanchez-Blazquez, 
et al. 2003). They have also looked at tolerance in this system. RGS9 knock-down mice 
had less tolerance after 4 daily morphine treatments (Garzon, et al. 2001). RGS14 ODN 
knock-down decreased MOR internalization by altering its phosphorylation in 
periaqueductal gray (PAG). These mice also had decreased tolerance (Rodriguez-Munoz, 
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et al. 2007b). Knock-down of RGS20/RGSZ1 and RGS17/RGSZ2 increased morphine 
analgesia, tolerance and tachyphylaxis (Sanchez-Blazquez, et al. 2005). This was not 
seen with DOR agonists DPDPE ([D-Pen2,5]-enkephalin), or [D-Ala2] deltorphin II 
(Garzon, et al. 2005b). Hence RGS proteins, particularly RGS9, regulate morphine 
analgesia and tolerance and are an attractive therapeutic target.  
 
RGS proteins are important for endocrine function. It is well established that 
G protein signaling is important for proper endocrine function (Lania, et al. 2006, Melien. 
2007). It is therefore reasonable to consider the roles of RGS proteins in theses systems.  
Diabetes. Type II diabetes develops when obesity and sedentary lifestyle results in 
decreased insulin sensitivity. The prevalence of obesity and diabetes is growing at an 
alarming rate and has reached epidemic levels (Smyth & Heron. 2006). RGS2 inhibited 
glucose-dependent insulinotropic peptide receptor (GIP-R, a Gαs coupled GPCR)-
mediated insulin release and was shown to bind Gαs. RGS2 mRNA levels were increased 
with GIP treatment in betaTC3 cells (Tseng & Zhang. 1998).  
But the most impressive demonstration of the involvement of RGS proteins in 
diabetes is the phenotype of the Gαi2 G184S knock-in mice. These mice have reduced 
weight gain and are protected from insulin resistance when fed a high fat diet compared 
to wild type mice (Huang, et al. 2008). The signaling pathways and RGS proteins 
involved were not identified, but this demonstrates the global importance of RGS 
proteins in the development of diabetes. Since these mice also have hypertrophy, 
hyperactivity, and increased neutrophil count (Huang, et al. 2006), a global RGS inhibitor 
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may not be desirable. However, if the RGS proteins involved in preventing insulin 
resistance could be identified, they would be attractive therapeutic targets.  
Reproductive hormones. RGS proteins have also been shown to be important in 
hormone receptor signaling. RGS3 but not RGS1, RGS2 or RGS4 inhibited gonadotropin 
releasing hormone (GnRH) mediated IP3 signaling through Gαq in COS-1 cells, and 
RGS3 is expressed in a gonadotropic cell line (Neill, et al. 1997). RGS3 has also been 
shown to inhibit GnRH mediated luteinizing hormone secretion from cultured rat 
pituitary cells (Neill, et al. 2001). RGS10 has also been shown to regulate this receptor 
(Castro-Fernandez & Conn. 2002). RGS3 but not RGS10 regulate signaling by follicle-
stimulating hormone and luteinizing hormone receptor (Castro-Fernandez, et al. 2004). 
The estrogen receptor α was shown to be regulated by RGS3 (also called steroid-
receptor-binding RGS, SRB-RGS) in a transcriptional read-out and this was due to a 
direct interaction (Ikeda, et al. 2001). This is an interesting observation as the estrogen 
receptor α is not a GPCR.  
Other hormones. RGS2 regulates parathyroid hormone and thyroid stimulating 
hormone-mediated signaling (Eszlinger, et al. 2004, Thirunavukkarasu, et al. 2002). 
RGS4, but not RGS7, RGS9 or RGS19 has been shown to inhibit thyrotropin releasing 
hormone receptor-mediated IP formation in HEK cells (Harder, et al. 2001). RGS4 is also 
important in melatonin receptor signaling. RGS4 knock-down with siRNA in CHO cells 
expressing the melatonin receptor attenuated receptor desensitization without affecting 
forskolin response (Witt-Enderby, et al. 2004). RGS4 and RGS10 blocked melatonin 
inhibition of androgen receptor reporter gene activity. This was shown to be through Gαq 
and Gαi mediated signaling, respectively (Rimler, et al. 2007). And finally, 
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overexpression of the RGS-insensitive Gαq in rats caused increased oxytocin and 
corticosterone responses with 5-HT2A/2C stimulation compared to overexpression of 
wild type Gαq (Shi, et al. 2006). 
 
RGS proteins regulate immune function. RGS1 mRNA is found in monocytes 
(Denecke, et al. 1999), RGS1, RGS3 and RGS13 mRNA are in B-cells (Moratz, et al. 
2000, Reif & Cyster. 2000, Shi, et al. 2002) and RGS2, RGS3, RGS4, RGS14 and 
RGS16 are in T-cells (Beadling, et al. 1999, Cho, et al. 2000, Johnson & Druey. 2002, 
Sato, et al. 2002). Natural killer cells contain RGS1, RGS2, RGS5, RGS8, RGS16, and 
RGS18 (Kveberg, et al. 2005). 
In B-cells, RGS1 inhibits platelet activating factor mediated increases in 
intracellular Ca+2 and stromal-derived factor-1-induced cell migration (Moratz, et al. 
2000). RGS1 or RGS3 overexpression diminishes chemotaxis toward certain chemokines 
(Reif & Cyster. 2000), and RGS1 overexpression in progenitor B cells impairs 
chemotaxis and adhesion. It is thought that this is involved in B-cell development as 
RGS1 levels increase as the B-cells mature (Le, et al. 2005). On the other hand, mice 
lacking RGS1 have B-cells that are overresponsive to chemokines and have improper 
desensitization (Moratz, et al. 2004). When injected into a wild type host, more B 
lymphocytes from RGS1 deficient mice home to the lymph nodes compared to cells 
isolated from wild type mice (Han, et al. 2005). RGS13 also impairs chemokine signaling 
(Shi, et al. 2002), and knock-down of RGS1 and/or RGS13 in a lymphoma cell line 
increases chemokine responsiveness (Han, et al. 2006b). In transfected 293T cells, wild 
type RGS14, but not a GAP deficient mutant, inhibited interleukin 8 mediated ERK 
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activation. Both the wild type and the mutant RGS14 inhibited Gα13 mediated serum 
response element activation (Cho, et al. 2000).  
T-cells from RGS2 deficient mice have lower levels of the growth factor 
interleukin-2 and reduced proliferation. This correlates with impaired antivirus responses 
in theses mice (Oliveira-Dos-Santos, et al. 2000). In T-cells, there is a correlation 
between decreased expression of RGS1, RGS9 and RGS16 and increased migration 
(Agenes, et al. 2005). Transgenic mice overexpressing RGS16 have T cells with impaired 
lung recruitment in response to inhaled allergen, but increased T-cell activation (Lippert, 
et al. 2003). 
Using RGS13 deficient mice, it was shown that RGS13 inhibits antigen induced 
mast cell activation and deficient mice had increased anaphylaxis. Interestingly, this was 
independent of its GAP function and not mediated by a GPCR (Bansal, et al. 2008). In 
lymphoid cells, RGS1, RGS3 and RGS4 inhibit migration towards chemoattractants 
(Bowman, et al. 1998). 
The Gai2 G184S knock-in mice mentioned above have enlarged spleens and 
increased neutrophil counts (Huang, et al. 2006). What this means for immunity is an 
interesting question for future work. 
 
1c RGS inhibition.  
 
It has been estimated that approximately 40% of all clinically used drugs target 
GPCRs (Eglen, et al. 2007). However, selectively activating the GPCR of interest is 
problematic due to the high homology between related receptors. As a result, many drugs 
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have unintended effects at non-target GPCRs and may result in various side effects. 
Another problem is that the same GPCR can activate multiple signaling pathways, as 
mentioned above. Because RGS proteins have limited G protein selectivity, receptor 
selectivity, and distinct expression patterns, it has been suggested that selective RGS 
inhibitors could potentiate a single signaling pathway by a certain GPCR in a specific 
area of the body. This could result in very targeted effects which would cause fewer side 
effects (Neubig. 2002, Traynor & Neubig. 2005, Zhong & Neubig. 2001). 
Individual examples of where an RGS inhibitor would be useful are outlined 
above and include treatments for hypertension (Cho, et al. 2008), PD (Ding, et al. 2006), 
pain (Rodriguez-Munoz, et al. 2007b), cocaine reward (Rahman, et al. 2003), asthma 
(Druey. 2003), and diabetes (Huang, et al. 2008, Usui, et al. 2004). Although not 
discussed in detail here, RGS proteins have also been suggested as useful cancer targets 
(Boss, et al. 2007, Heo, et al. 2006). 
For these reasons, the Neubig and Mosberg labs have been interested in targeting 
RGS proteins. RGS4 was chosen for the initial efforts because it is a prototypical member 
of the R4 family and the first with a crystal structure that could be used for rational 
design (Tesmer, et al. 1997). The goal of this project was to identify new and more potent 
inhibitors of RGS4 than our lead compound.  
 
There are three approaches to developing an inhibitor to a protein. The first 
approach is rational design based on a structure. For this, the crystal structure of RGS4 
bound to Gαi1 was used (Tesmer, et al. 1997). The strategy employed in these studies was 
to create a peptide that blocks the RGS4-Gα interaction by mimicking a piece of the G 
 30   
protein. Initially, two peptides with the sequences of two of the three switch regions on 
the Gα protein were purchased but they were found to be inactive. It was then determined 
that a structurally constrained analog of the switch 1 region would be a better approach. 
The resultant peptide, YJ34 (Ac-Val-Lys-c[Cys-Thr-Gly-Cys]-Glu-NH2, S-S) and a series 
of related peptides represented the first published RGS4 inhibitors (Jin, et al. 2004). 
Mechanistic and structure-activity relationship (SAR) studies on YJ34 will be discussed 
in Chapter 2. 
The second approach is high-throughput screening (HTS). For this approach a 
large number (thousands or millions) of compounds are screened for activity. The 
advantage of this approach over the rational approach is that a large number of 
compounds can be tested more rapidly. As with all HTS-related screening endeavors, 
there is considerable time and effort committed to evaluating the hits; true hits have to be 
distinguished from false positives, and the mechanisms have to be determined (Keseru & 
Makara. 2006). This method has been used to identify small molecule inhibitors of 
RGS4. In a screen in yeast, some compounds were identified, but no structures were 
published (Young, et al. 2004). Recently, in the Neubig lab, Roman et al (2007) 
identified CCG-4986, a small molecule RGS4 inhibitor (Roman, et al. 2007). The method 
used for this study will be mentioned in Chapter 4. 
The third approach is computational. In silico screening of virtual libraries has the 
advantage of being much faster and affordable than physically screening compounds 
once an appropriate algorithm has been established. But there are challenges to screening 
for inhibitors of a protein-protein interaction, and although there have been advances 
(Headd, et al. 2007), this approach was not chosen for this study.  
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The plan for this project was to utilize a combination of rational and 
combinatorial design in order to identify novel peptide inhibitors. There are features of 
YJ34 that were found to be necessary for function (Chapter 2). These structures were 
constrained in the library, while the other positions were randomized to afford a 2.5-
million peptide library, which will be discussed in detail in Chapters 3 and 4. The hope 
was that by using a focused library, the likelihood of identifying peptides that had the 
same mechanism of action as YJ34 would be increased.  
There are several methods that can be employed in a peptide library approach. 
The first approach utilizes positional scanning peptide libraries, which are a series of 
soluble peptide sub-libraries where one position is fixed while the other positions are 
randomized. There is one sub-library for each amino acid at each position, and the top 
few sub-libraries at each position are chosen. Peptides made that combine the best amino 
for each position are then synthesized (Pinilla, et al. 1992). Many have used this approach 
successfully and it has been especially useful in identifying protease substrates (Choe, et 
al. 2006, Cuerrier, et al. 2007, Diamond. 2007, Schmid, et al. 2007). In order to employ 
this method, a solution based high-throughput assay for testing peptide activity would be 
needed. 
A second peptide library method is phage display. For this approach, DNA 
encoding peptides are fused to bacteriophage coat proteins. Bacteriopage libraries are 
screened by virtue of their capacity to bind a tethered target (Cesareni. 1992). Although 
others have had success with it in the past (McLafferty, et al. 1993), there were concerns 
about proper formation of the disulfide bond within the peptide library. Another 
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disadvantage of this kind of library is that unnatural amino acids and N- and C-terminal 
modifiers cannot be incorporated.  
The method chosen for this project was a one-bead, one-compound (OBOC) 
library. This kind of library is synthesized and screened on beads and it is designed such 
that each bead has only one sequence and the beads that bind a fluorescent protein are 
isolated (Lam, et al. 1991). The isolated beads are then sequenced by Edman degradation 
to afford the hit sequences. This method was chosen with the assumption that the 
screening would be more straightforward than a soluble peptide library screen. Also, 
since the library is synthetic, N- and C-terminal modifiers could be incorporated, an 
option that is not possible with a phage display approach. The details and results of this 
will be discussed in Chapters 3 and 4.  
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Mechanism of Action and Structural Requirements of Constrained 







Regulators of G Protein Signaling (RGS) accelerate GTP hydrolysis by Gα 
subunits and profoundly inhibit signaling by G protein-coupled receptors. The distinct 
expression patterns and pathophysiologic regulation of RGS proteins suggest that 
inhibitors may have therapeutic potential. The Mosberg and Neubig labs previously 
reported the design of a constrained peptide inhibitor of RGS4 (YJ34: Ac-Val-Lys-[Cys-
Thr-Gly-Ile-Cys]-Glu-NH2, S-S) based on the structure of the Gαi switch 1 region but its 
mechanism of action was not established. In this Chapter, it is shown that YJ34 inhibits 
RGS4 activity in a single-turnover GTPase accelerating protein (GAP) assay. 
Furthermore, a mutation in Gα (G183S) that disrupts binding of RGS4 to the Gα subunit 
also disrupts activity of the Gα mimetic peptide, suggesting that YJ34 binds the RGS 
protein in the same manner that Gα does. Also, YJ34 shows selectivity for RGS4 and 
RGS8 vs. RGS7 and structure activity relationships illustrate key features for RGS 
inhibition. Finally, the capacity of the methylene dithioether-bridged peptide inhibitor, 
YJ33, to modulate muscarinic receptor-regulated potassium currents in atrial myocytes is 




inhibitors, demonstrate their action in native cells, and provide a starting point for the 
design of RGS inhibitory drugs.  
 
Materials and Methods: 
 
Materials: Fmoc-protected amino acids and Rink amide resin were purchased 
from Advanced ChemTech (Louisville, KY). Pre-loaded PEG-PS resin and peptide grade 
synthesis chemicals were purchased from Applied Biosystems (Foster City, CA). 
γ[32P]GTP (10 mCi/ml) was purchased from Amersham (Piscataway, NJ), or from Perkin 
Elmer (Boston, MA) and diluted in unlabeled GTP to the desired level of radioactivity. 
  
Protein Expression and Purification: His6-Gαo (rat), His6-RGS4 (rat), GST-
RGS7box (human, nucleotides 915-1359) and GST-RGS8 (rat, nucleotides 315-857) 
were expressed and purified according to previous protocols (Lan, et al. 1998, Lan, et al. 
2000, Lee, et al. 1994). Hualing Zhong made some of the proteins used. 
 
Peptide Synthesis: Peptides were synthesized and cyclized as described 
previously (Jin, et al. 2004). Resin was treated with piperidine (Aldrich, Milwaukee, WI, 
USA) to cleave the Fmoc-protecting group, then the first amino acid was coupled with o-
benzotriazol-1-yl-N,N,N',N'-tetramethyl uronium hexafluorophosphate (HBTU) and 1-
hydroxybenzotriazole (HOBt) (Applied Biosystems). Trifluoroacetic acid (TFA)/water/ 
dithioethane (90:5:5) or  TFA/phenol/water/triisopropylsilane (TIPS) (88:5:5:2) was used 




protecting groups. The peptide solution was filtered from the resin and then subjected to 
preparative reverse-phase high-performance liquid chromatography (RP-HPLC) to afford 
the linear disulfhydryl-containing peptide with a purity of at least 90%. Yafei Jin, 
Katarzyna Sobczyk-Kojiro, Joe Musleh, Eric Schneider, Liangcai Gu or myself 
synthesized the YJ, KSK, JM, ES, GU, and BR peptides respectively. 
 
Cyclization of Linear Peptides: For disulfide formation, linear disulfhydryl-
containing peptides were dissolved (1mg/ml) in 1% acetic acid, 0.1 % trifluoroacetic 
acid, 2M urea in N2 saturated water on ice. The pH of the peptide solution was raised to 
8.5 using NH4OH, followed by the addition of 4 mol equivalents of K3Fe(CN)6. The 
reaction mixture was stirred for 1 min, and quenched with acetic acid to a pH 3.5 or less. 
The mixture was then subjected to HPLC. 
To form dithioether or dithiomethyl-containing cyclic peptides, a linear 
disulfhydryl peptide was added to dimethylformamide on ice under a N2 atmosphere (0.1 
mg linear peptide/mL dimethylformamide). Five mole equivalents of potassium tert-
butoxide were added to the peptide solution, followed by the addition of 2.5 mol 
equivalents of Br-(CH2)n-Br (n=1 or 2). The reaction was quenched with 2 mL acetic acid 
after 2 h and the solvent was removed in vacuo. The residue was dissolved in water, 
filtered, and then subjected to HPLC. 
All final product peptides were at least 95% pure as assessed by RP-HPLC on a 
Vydac 218TP C-18 column (The Nest Group, Southboro, MA, USA) using the solvent 




component in 90 min. All peptides displayed the appropriate molecular weights as 
determined by mass spectrometry. 
 
RGS-Stimulated GTPase: Single turnover GTP hydrolysis measurements with 
and without RGS were based on Lan, et al. (1998) and adapted to a 96 well plate format. 
Briefly, 200 to 800 nM Gαo was loaded with a 2-3 fold molar excess of γ[32P]GTP in 20 
mM Hepes, 20 mM EDTA pH 8.0 for 5 or 20 minutes at room temperature and then 
cooled on ice. In some cases, the loaded Gαo was gel filtered through a 1 ml G-25 
sephadex spin column to remove unbound γ[32P]GTP. The loaded Gαo was then added to 
equal volumes of ice-cold initiation buffer (20 mM Hepes, 40 mM MgCl2 pH 8.0 and 5-
20 µM unlabeled GTP) containing RGS and/or peptide. The concentration of RGS 
protein (15-500 nM) was varied to keep the uninhibited rate of GTP hydrolysis less than 
5.5 min-1. This variation in RGS concentration was needed because of different activities 
of the protein preparations, different activities of the various RGS proteins against Gαo, 
and different concentrations of Gαo used. After incubation for various times on ice, the 
reaction was quenched with 5% activated charcoal in buffer containing 20 mM sodium 
phosphate buffer (pH 2.0). After 20 minutes, the charcoal was centrifuged and the 
supernatant counted in a Perkin Elmer TopCount 96 well plate counter by Cerenkov 
counting. The amount of [32P] Pi released at each time point was fit to an exponential 
function: 
 [32P] Pi counts(t) = counts(t=0) + counts(t=30 min)*(1-e-kt) 
 
Where counts t=0 represents the counts per minute (cpm) obtained before the addition of 




which was calculated using GraphPad Prism (San Diego, CA). Fitting constraints 
included setting counts(t=0) for each curve to the average of the counts(t=0) for the 
experiment, and setting counts(t=30 min) to the same value for all curves in an experiment. 
Peptide activity is determined from the percent decrease in RGS stimulated GTPase rate 
constant. 
 
Electrophysiology: All animal studies were performed by Masaru Ishii according 
to the guidelines of the ethical committee of Osaka University Graduate School of 
Medicine. Single rat atrial myocytes were enzymatically isolated from hearts removed 
from adult male Wister-Kyoto rats as described elsewhere (Ishii, et al. 2001). Briefly, rats 
were deeply anesthetized by intraperitoneal injection of pentobarbital. A cannula was 
inserted into the aorta, and the heart was perfused in a retrograde manner through the 
coronary arteries. The heart was digested by collagenase (Boehringer Mannheim, 
Ingelheim, Germany) in nominally Ca2+-free solution at 37°C for 10 min. Dissociated 
myocytes were seeded on glass coverslips (15 mm diameter) which had been coated with 
poly-D-lysine (Sigma, Milwaukee, WI) kept in a humidified environment of 0.5% CO2 at 
37°C, and cultured with medium M199 (PAA laboratories, Etobicoke, Ontario, Canada) 
containing gentamycin and kanamycin (25 mg/L each) for 2-4 days. Muscarinic-receptor 
regulated KG channel (GIRK) currents in atrial myocytes were measured using whole-
cell mode patch clamp method as previously described (Ishii, et al. 2001). The whole-cell 
currents were measured at room temperature by a patch-clamp amplifier (Axon 200A, 
Molecular Devices, Sunnyvale, California) and recorded on videocassette tape with a 




available software (Patch Analyst Pro, MT Corporation, Los Angeles, California) after a 
low-pass-filtration at 1 kHz (-3 dB) by an eightpole Bessel filter, sampled at 5 kHz. The 
control bathing solution contained (in mmol/L): 115 NaCl, 20 KCl, 1.8 CaCl2, 0.53 
MgCl2, 5.5 glucose, and 5.5 Hepes-NaOH, pH 7.4. The pipette (internal) solution 
contained (in mmol/L): 150 KCl, 5 EGTA, 1 MgCl2, 3 K2ATP, 0.1 Na2GTP, and 5 
Hepes-KOH (pH 7.3). The ACh-induced GIRK currents were obtained by digitally 
subtracting currents recorded under control conditions from those recorded in the 
presence of ACh. Three parameters of RGS action on GIRK currents, i.e., time course of 
onset (kon) and offset (koff) of KG current and degree of relaxation (Iins/Imax), were 
determined (Ishii, et al. 2001). Peptide YJ33 was applied intracellularly through the patch 
capillary electrode. Peptide YJ33 was first dissolved into DMSO as 15 mM stock, and 
then diluted at 1/100 into patch electrode internal solution (final internal solution 
contained 150 µM peptides and 1% (v/v) DMSO).  
 
Statistical Analysis: Data are expressed as mean ± S.E.M. and analyzed by either 
a 2-tailed unpaired t-test or a one-way ANOVA with a Dunnett’s post-test. Significance 




YJ34 Inhibits RGS4 GAP activity in a single turnover GTPase assay. It has 
been previously shown that YJ34, a constrained peptide mimetic of the switch 1 region 




assay (Jin, et al. 2004). To determine whether the results seen previously are due to YJ34 
activity on the RGS4 protein or whether it has its activity on the receptor or other proteins 
or lipids in the membrane preparation, YJ34 activity was measured in a single turnover 
GTPase assays with purified proteins. RGS4-enhanced hydrolysis of Gαo-bound 
γ[32P]GTP was measured in the presence and absence of YJ34. RGS4-stimulated Gαo 
GTPase activity is inhibited by YJ34 in a dose-dependent manner (Figure 2.1) with an 
IC50 of 9 µM. It should be noted that YJ34 was tested up to only 40 µM (i.e. less than 
half its aqueous solubility limit) in order to avoid aggregation. Consistent with previous 
results in a membrane GTPase assay (Jin, et al. 2004), the methylene dithioether-bridged 
peptide YJ33, was active but had lower potency than did the disulfide-bridged peptide 














Figure 2.1: YJ34 inhibits RGS4 in a single turnover GTPase assay. The rate of GTP 
hydrolysis was measured with no RGS, 100 nM RGS4, or 100 nM RGS4 with increasing 






Name Sequence % Inhibition 
(100 µM unless 
otherwise noted) 
Gα  …180Val-Lys-Thr-Thr-Gly-Ile-Val-Glu187…  
YJ34 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 75 ± 3  (40 µM) 
YJ33 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-CH2-S) 25 ± 7 
                                                     Gly Substitutions: 
BR2 Ac-Val-Lys-c[Cys-Thr-Ser-Ile-Cys]-GluNH2 (S-S) -10 ± 8 
YJ37 Ac-Val-Lys-c[Cys-Thr-D-Ser-Ile-Cys]-GluNH2 (S-S) 59 ± 4 (30 µM) 
YJ47 Ac-Val-Lys-c[Cys-Thr-D-Pro-Ile-Cys]-GluNH2 (S-S) 1 ± 14 
                                                    N-terminal modifications: 
BR13 NH2-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 2 ± 8  
YJ41 Ac-   -Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 8 ± 11 
BR7 Arg-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 (S-S) 4 ± 9 
BR1 Arg-Thr-Arg-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluNH2 
(S-S) 
13 ± 10 
                                                    C-terminal modifications: 
YJ49 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-GluOH (S-S) 1 ± 11 
YJ42 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Cys]-   -NH2 (S-S) 3 ± 29 
                                                   Thr substitutions: 
YJ45 Ac-Val-Lys-c[Cys-Ser-Gly-Ile-Cys]-GluNH2 (S-S) 73 ± 3 
YJ46 Ac-Val-Lys-c[Cys-Ala-Gly-Ile-Cys]-GluNH2 (S-S) 53 ± 10 
BR8 Ac-Val-Lys-c[Cys-Lys-Gly-Ile-Cys]-GluNH2 (S-S) 19 ± 15 
                                                     Cys substitutions: 
BR5 Ac-Val-Lys-c[Pen-Thr-Gly-Ile-Cys]-GluNH2 (S-S) -9 ± 10 
BR6 Ac-Val-Lys-c[Cys-Thr-Gly-Ile-Pen]-GluNH2 (S-S) -2 ± 2 
KSK99A Ac-Val-Lys-c[Cys-Thr-Gly-Ile-D-Cys]-GluNH2 (S-S) 10 ± 17 
                                                    Ile substitutions: 
GU1 Ac-Val-Lys-c[Cys-Thr-Gly-Met-Cys]-GluNH2 (S-S) 22 ± 9 
GU2 Ac-Val-Lys-c[Cys-Thr-Gly-Met-Cys]-Glu-NH2  
(S- CH2CH2-S) 
61 ± 11 
YJ36 Ac-Val-Lys-c[Cys-Thr-Gly-Phe-Cys]-GluNH2 (S-S) 38 ± 10 
ES2 Ac-Val-Lys-c[Cys-Thr-Gly-Phe-Cys]-GluNH2  
(S- CH2CH2-S) 
52 ± 12 (30 µM) 
 
Table 2.1: Sequences and RGS4 inhibition of various peptide analogs of YJ34. 
(S-S), (S-CH2-S), (S-CH2CH2-S), indicate cyclization via disulfide, methylene 




Gly183 is critical for peptide-mediated inhibition of RGS4 GAP activity. It is 
possible that YJ34 could bind to either the Gα subunit or RGS4. In order to determine the 
target of the peptide inhibitors, BR2 was made to mimic the RGS insensitive G183S 
mutant of Gαi. If YJ34 binds to RGS4 in the same manner that the switch 1 region of Gαi 
binds, then a mutation that disrupts this binding in the Gαi subunit should also disrupt 
binding of YJ34. As predicted, BR2 does not inhibit RGS4 activity at a concentration 
that is nearly 4 times greater then YJ34 (150 µM), (Figure 2.2 and 2.3A), suggesting that 
YJ34 binds to RGS4 as designed, by mimicking the Gα subunit. BR2 does not bind, 
perhaps due to a direct steric clash of the Ser side chain with RGS4 or through 
conformational effects at the β-turn. YJ37 was also prepared, using D-Ser in place of the  
Gly, since D-Ser (unlike L-Ser) is compatible with the β-turn present in the Gα switch 1-
RGS4 contact. Interestingly, YJ37 displayed similar inhibitory properties as YJ34 (Table 
2.1, and Figure 2.3A). A D-Pro analog, YJ47, was ineffective at inhibiting RGS4 
activation of Gαo, confirming that the structure of the constrained peptide is important 
(Table 2.1 and Figure 2.3A). This is not surprising since Gly183 is important for Gαi-








      
 
 
Figure 2.2: Gly183 is required for peptide activity at RGS4. A) Single turnover GTPase 
assays were preformed as described with no RGS, 100 nM RGS4, 100 nM RGS4 with 40 
µM YJ34, and 100 nM RGS4 with 150 µM BR2. This graph is representative of 2 
experiments done in duplicate. B) Rates were calculated from the data in A as described. 





Structure activity relationship results. In order to better understand which 
structural components of YJ34 contribute to its activity, and in hope of identifying more 
potent inhibitors, several additional modifications to the structure of YJ34 were 
examined. The inhibition of RGS4 GAP activity by each peptide at 100 µM 
concentration was measured using the single turnover GTPase assay and the data are 
summarized in Table 2.1. By comparison, YJ34 inhibits RGS4 stimulated GTPase 
activity by 75 ± 3 percent at 40 µM (p=0.0004 compared to control).  
In YJ34, incorporation of the N-terminal acetyl and C-terminal carboxamide was 
chosen to best correspond to the internal ‘parent’ sequence in Gαi. In order to examine 
whether such uncharged termini and the octapeptide framework of YJ34 are optimal, 
BR13, YJ41, BR7, BR1, YJ49, and YJ42 were prepared. As shown in Table 2.1, 
analogs with a free N-terminal amine (BR13) or a C-terminal carboxylate (YJ49) were 
inactive (Table 2.1 and Figure 2.3B). Truncation of the peptide from either the amino 
terminal (YJ41) or carboxy terminal (YJ42) end also abolishes activity (Table 2.1 and 
Figure 2.3B). N-terminal elongation of the peptide by either the previous 1 or 3 amino 
acids in the sequence of Gαi1 (BR7 and BR1, respectively) also resulted in complete loss 
of activity (Table 2.1 and Figure 2.3B). These suggest that the peptide length and the 
absence of charged termini are critical for peptide activity. 
The Thr182 of Gαi makes several contacts with RGS4 including interactions with 
polar (Glu87, Asp163) and nonpolar (Leu159) side chains (Tesmer, et al. 1997). It is 
therefore not surprising that changing the Thr of YJ34 to Ala, lacking the polar hydroxyl 
group, decreases activity (YJ46, 53 ± 10 percent inhibition of RGS activity at 100 µM, 




activity (YJ45, 73 ± 3 percent inhibition of RGS4 activity at 100 µM, Table 2.1 and 
Figure 2.3C). Substitution of Lys for Thr, with the intention of facilitating a salt bridge 
with Glu87 of RGS4, was unsuccessful, demonstrating very low inhibitory activity (BR8, 
Table 2.1 and Figure 2.3C) 
The structure/conformation of the peptide cycle is also important for activity. In 
agreement with earlier studies (Jin, et al. 2004), increasing the cycle size from the 
disulfide of YJ34 to the methylene dithioether bridge of YJ33 reduces potency. The latter 
peptide inhibited RGS4 activity by 25 ± 7 percent at 100 µM. Thus the estimated IC50 for 
YJ33 is approximately 300 µM, significantly less potent than the disulfide-bonded YJ34 
(Figure 2.3 and Table 2.1). Substitution of either disulfide bridge Cys by the more rigid 
penicillamine (Pen) resulted in complete loss of activity (BR5, BR6, Table 2.1 and 
Figure 2.3C). Substitution of the second Cys with D-Cys also resulted in a complete loss 
of peptide activity (KSK99A, Table 2.1 and Figure 2.3C). Linear peptides have no 
activity (Jin, et al. 2004, data not shown). The Ile184 residue of Gαi appears to form a 
Van der Waals contact with Tyr84 of RGS4. It was found that other hydrophobic residues 
at this position (GU1, GU2, YJ36, and ES2) also had some activity (Table 2.1 and 
Figure 2.3C). In particular, peptides with substitution of Met (GU1 and GU2) inhibit 
RGS4 activity by 22 ± 9 and 61 ± 11 percent at 100 µM (Table 2.1 and Figure 2.3C), and 
Phe (YJ36 and ES2) inhibits 38 ± 10 and 52 ± 12 at 100 µM and 30 µM respectively. 
Interestingly, the ethylene dithioether-bridged GU2 and YJ36 are more active then the 







Figure 2.3: Inhibition of RGS4 by analogs of YJ34. Peptides (from Table 2.1) were 
tested in a single turnover GTPase assay at 100 µM (unless otherwise indicated) and 
percent inhibition of RGS4-stimulated GTP hydrolysis rate is shown. The modifications 
from YJ34 at the indicated position are shown after the peptide name. Inhibition of RGS 
activity by peptides with modifications from YJ34 at the Gly position (A), at the N or C 
termini (B), or at the Thr, Cys or Ile (C) positions was determined. These graphs are the 
average of experiments done in duplicate, triplicate or quadruplicate (mean ± S.E.M., n 




YJ34 and YJ33 show RGS specificity. The concentration-dependent effect of 
YJ34 on the rate of RGS-stimulated GTP hydrolysis was also measured for RGS7 and 
RGS8. The IC50 of YJ34 on RGS4, RGS7 and RGS8 is 9 µM, 43 µM and 11 µM 
respectively (Figure 2.4A). RGS4 and RGS8 are approximately 4-fold more sensitive to 
YJ34 than RGS7. It has previously been demonstrated that longer bridges within the 
same sequence as YJ34 behave as less potent peptides inhibitors of RGS4 (Jin, et al. 
2004). The methylene dithioether bridged peptide, YJ33, is the second most potent 
peptide with this sequence and appears to be selective for RGS4 over RGS8 but has no 
effect on RGS7 at 100 µM (Figure 2.4B). Interestingly, the ability of an RGS to be 
inhibited by YJ34 correlates with that RGS protein’s catalytic efficiency for Gαi1 and 















   
 
Figure 2.4: YJ34 and YJ33 have greater activity for RGS4 and RGS8 than RGS7. A, 
Rate constants were calculated as described from Fig. 1, for no RGS, RGS4, RGS7, and 
RGS8 with various concentrations of YJ34. These graphs are the average of three 
(RGS4, no RGS at 40 µM YJ34), four (RGS7 and RGS8) or five (no RGS, 0 µM YJ34) 
experiments done in duplicate (mean ± S.E.M). *p<0.05, **p<0.01, ***p<0.001 
compared to RGS4. B, Percent inhibition of the rate of RGS4, RGS7 and RGS8 
stimulated GTP hydrolysis by 100 µM YJ33 was measured. This is the average of two to 
eight experiments done in triplicate (mean ± S.E.M.) *p<0.05, **p<0.01, ***p<0.001 




Peptide 2 inhibits RGS regulation of GIRK currents in cardiac myocytes. To 
determine whether the peptide inhibitors act in a physiological system and to demonstrate 
a role of RGS proteins in ion channel regulation, the well-characterized muscarinic GIRK 
currents in atrial myocytes and a whole-cell patch-clamp pipette to deliver the peptides to 
the intracellular space was used. YJ34 had no effect on GIRK currents (not shown), 
presumably due to residual reducing equivalents in the cell that reduced the essential 
disulfide bond. The methylene bridged peptide YJ33, however, did reduce the degree of 
current relaxation (Figure 2.5A and Ca) and slowed the rate of onset and offset of the 
muscarinic response (Figure 2.5B, Cb and Cd). In some experiments (Figure 2.5Ab and 
Bb) the effect was not seen. Overall, however, there was a statistically significant effect 





















Figure 2.5: Inhibition of RGS effects on GIRK currents in atrial myocytes by YJ33. A, 
Representative tracings of currents evoked by 0.1 (left) or 1 (right) µM acetylcholine in 
the presence (a and b) or absence (c) of 150 µM YJ33, 1% DMSO. Sections a and b 
show the variation of responses to YJ33. Currents at -100 mV were recorded after 
prepulses at -100 to + 40 mV in steps of 20 mV. Baseline currents at 0 µM acetylcholine 
were subtracted out. Arrows indicate the end point of the instantaneous and the start point 
of the relaxing components of the currents. Vertical bars represent 500 pA, and horizontal 
bars indicate 1 sec. B, Representative tracings of deactivation (left) and activation (right) 
of GIRK currents in the presence (a and b) and absence (c) of 150 µM YJ33, 1% DMSO. 
Sections a and b show the variation of responses to peptide YJ33. Arrows indicate the 
endpoint of deactivation or activation and the horizontal bar indicates 10 s. C, IIns/Imax, 
(a), T1/2 (deactivation) (b) and T1/2 (activation) (c) were calculated in the presence (left) and 
absence (right) of 150 µM YJ33 from A and B and are shown for individual cells. The 















Mechanism of action. YJ34 was designed based on the crystal structure of the 
RGS4-Gαi complex in the presence of GDP•AlF4-. The peptide attempts to mimic the 
switch 1 region of Gαi, a constrained loop that makes considerable contacts with RGS4.  
It was designed to bind to RGS4 and competitively inhibit Gα/RGS interactions and thus 
inhibit RGS4 activity. It was previously shown that YJ34 inhibits RGS4 activity in a 
steady state GTPase assay (Jin, et al. 2004) using cell membranes. In the present study, it 
is demonstrated that YJ34 also inhibits RGS4 activity in a single turnover GTPase assay 
using purified proteins. The results of these assays suggest that YJ34 is interacting 
directly with RGS4 protein rather than with other proteins or lipids found in the 
membrane preparation, although data in Figure 2.1 is not inconsistent with YJ34 being a 
Gαo inhibitor. Since YJ34 had little to no effect on the GTP hydrolysis by Gα (Figure 
2.4A, Jin, et al. 2004), is concluded that YJ34 is most likely acting directly on the RGS 
protein. This is supported by data that will be discussed in Chapter 3 showing that YJ34 
on beads does bind RGS4. 
 To determine whether the mode of interaction of YJ34 with RGS truly mimics the 
Gα subunit interaction, BR2 was designed to mimic the switch 1 region of the RGS-
insensitive G183S mutant of Gαi (Table 2.1). The Gly to Ser mutation in the Gα subunit 
prevents RGS4 binding (Lan, et al. 1998). It is therefore hypothesized that if YJ34 bound 
to RGS4 the same way as switch 1 of Gαi, then a Gly to Ser modification would prevent 
peptide inhibition of RGS4 GAP activity. At almost 4 times the maximal concentration of 




in both Gα and in YJ34 is essential for binding to RGS4. These data further support the 
notion that YJ34 mimics the switch 1 region of Gα to block RGS4 activity on Gαo. 
 Also in support of the proposed mode of action, YJ34 exhibits significant RGS 
subtype selectivity. Because YJ34 has little direct effect on the catalytic activity of Gαo 
alone (Figure 2.4 and Jin, et al. 2004), and because it displays selectivity for certain RGS 
proteins (Figure 2.4A), it is believed that the peptide inhibitor is directly binding to and 
inhibiting the RGS protein, rather than to the Gα protein. Although it is less potent, YJ33 
appears to have similar RGS selectivity and likely shares a similar mechanism of action 
(Figure 2.4B). 
In the present study, it was found that YJ34 had an IC50 of 9 µM against RGS4 
(Figure 2.4A) while in the previous report, in a membrane steady state GTPase assay, it 
was less potent with an IC50 of 26 ± 2 µM (Jin, et al. 2004). YJ34 inhibited RGS4 81% at 
40 µM in a capillary electrophoresis assay with Gαo (Jameson, et al. 2005), which is in 
good agreement with the 75 ± 3% inhibition seen here (Table 2.1). For RGS8, 40 µM 
YJ34 inhibited 38 % and 74± 23 % in the capillary electrophoresis and in the single 
turnover GTPase assays, respectively (Jameson, et al. 2005 and Figure 2.4A). Both 
assays using purified proteins give similar results. However there are several differences 
between these systems and the membrane-based steady state GTPase assay that may 
contribute to the disparate activities observed. These include the presence of other 
proteins (including endogenous RGS proteins), various G proteins, the presence of 
membranes and different temperatures (30 oC in the steady state assay and ice cold for 
the single turnover assay). In addition, the steady state and the single turnover GTPase 




comparison. The difference is even greater for YJ33 (Table 2.1). Here it is shown that 
RGS4 is inhibited 24 ± 5 percent by 100 µM YJ33 for an IC50 of about 300 µM 
compared to an IC50 of 79 ± 6 µM in the steady state GTPase assay (Jin, et al. 2004). 
  
Structure-Activity Relationships of Peptide Inhibitors. Although Val179 and 
Glu186 of Gαi do not appear to make direct contacts with RGS4 (Tesmer, et al. 1997), 
these residues, with their N- and C-terminal charges blocked, appear to be necessary for 
peptide activity (Table 2.1). Perhaps the absence of constraints from the rest of Gα allows 
these residues and modifiers to make contacts with RGS4 that the switch 1 of Gαi could 
not normally make. It is likely that the charges on the free N- or C-termini interfere with 
binding to RGS4 via adverse electrostatic interactions and the terminal acetyl and amide 
groups of YJ34 prevent these negative interactions.  
The Thr182 of Gαi makes contacts with several residues in RGS4 including Glu87 
and Asn88, (Tesmer, et al. 1997). It is therefore not surprising that changing the Thr of 
YJ34 to Ala decreases its activity as an RGS4 inhibitor (YJ46, Table 2.1 and Figure 
2.3C), while a more conservative Ser substitution retains considerable activity (YJ45, 
Table 2.1 and Figure 2.3C). Glu87 and Asn88 of RGS4 form hydrogen bonds with the 
hydroxyl group on Thr182 of Gαi (Tesmer, et al. 1997). It is expected that similar 
interactions are made with the hydroxyl group of Ser in YJ45. It was proposed that a Lys 
in this position might interact with Glu87 on RGS4 and enhance its inhibitory effect, 
however the Lys substitution for Thr abolishes activity (BR8, Table 2.1 and Figure 2.3C). 
It is interesting to note that Gα12 has a Lys at this position in switch 1, and is not a 




 Ile184 of Gαi may form a Van der Waals contact with Tyr84 of RGS4. It is 
therefore not surprising that a peptide with a Met at this position still retains activity as an 
RGS inhibitor (Table 2.1 and Figure 2.3C). It is interesting that GU2, with an ethylene 
dithioether bridge, is more active than GU1 with a disulfide bridge. This is also the case 
with Phe substitutions for Ile (YJ26 and ES2, Table 2.1 and Figure 2.3C).  The opposite 
is true for the peptides with the Ile at this position (Jin, et al. 2004). Perhaps the alternate 
conformation of the ethylene bridge positions the Met to make better contact with the 
RGS4 protein. However, neither peptide is as potent as YJ34.  
 
Peptide RGS inhibitor effects on cardiac GIRK current. This inhibition of 
RGS-dependent phenomena in atrial myocytes by peptide YJ33 is the first demonstration 
of the actions of an RGS inhibitor in a physiological system. The magnitude of the effect 
is only modest but is consistent with the IC50 of this peptide at RGS4. The 25% inhibition 
of in vitro single turnover GAP activity seen at 100 µM YJ33 (Figure 2.4B) and the 25-
35% inhibition of kon, koff and Iins/Imax seen in the patch clamp studies (Figure 2.5C) with 
150 µM YJ33 are both consistent with a Ki of about 300 µM. The RGS proteins that are 
known to be expressed in rat atrial myocytes are RGS2, RGS3, RGS4, RGS6, RGS10, 
RGS17/RGSZ2, and RGS19/GAIP (Doupnik, et al. 2001). Since GIRK currents are 
primarily regulated by Gαi, (Sowell, et al. 1997) and RGS2, RGS6, and RGS17/RGSZ2, 
act primarily on Gαq, Gαo, and Gαz, respectively, RGS3, RGS4, RGS10, and 
RGS19/GAIP are the best candidates for controlling the kinetics of GIRK currents. 
Peptide YJ33 inhibits RGS4 and the sequence similarity of the RGS domain of these 




that peptide YJ33 may inhibit multiple RGS proteins that may be involved in Gαi and 
GIRK current regulation.   
Although the Mosberg and Neubig labs are the first to design and synthesize 
peptide inhibitors of RGS proteins, peptide inhibitors have been made against numerous 
biological targets including ribonucleotide reductase, (Cooperman, et al. 2005) protein 
kinases (Hines, et al. 2005) and bacterial membranes as antibacterial peptides (Rezansoff, 
et al. 2005). Here the modest specificity of the constrained peptide RGS inhibitors YJ34 
and YJ33 (RGS4 ≥ RGS8 > RGS7) are shown, evidence for the predicted mechanism of 
the peptide is provided, and activity in a native cell system are shown. Additional work 
will clearly be needed to enhance the potency of the peptides, more completely define the 
RGS specificity, and to develop RGS inhibitors that are cell-permeable for more general 
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Chapter 2 discusses the first RGS inhibitor, YJ34 (Ac-Val-Lys-c[Cys-Thr-Gly-
Ile-Cys]-Glu-NH2, S-S) (Jin, et al. 2004). This peptide was designed to mimic the switch 
1 region of the Gα subunit and was modeled from the RGS4-Gαi1 crystal structure 
(Tesmer, et al. 1997). It has a sequence similar to the switch 1 region with 2 amino acid 
substitutions (Thr181 to Cys and Val185 to Cys) to incorporate a disulfide bridge, which 
constrains the peptide in the correct conformation (Jin, et al. 2004, Roof, et al. 2006, 
Chapter 2). This peptide has an IC50 of 26 µM in a membrane based steady state GTPase 
assay (Jin, et al. 2004), a 9 µM IC50 in a purified protein single turnover GTPase assay 
(Roof, et al. 2006 Chapter 2), inhibits RGS4 81% at 40 µM in a capillary electrophoresis 
assay (Jameson, et al. 2005), and an analog inhibits RGS modulation of GIRK current 
kinetics in atrial myocytes (Roof, et al. 2006, Chapter 2). It was found that BR2 (Ac-Val-
Lys-c[Cys-Thr-Ser-Ile-Cys]-Glu-NH2, S-S), a peptide that mimics the RGS-insensitive 
G184S mutation in the Gα protein is inactive, suggesting that the peptide binds to RGS4 
as designed (i.e. in the same way the Gα switch 1 binds). SAR studies on this peptide 




acetyl group, C-terminal amide, the Gly at position 5, and Cys at positions 3 and 7 with a 
disulfide bridge (Roof, et al. 2006, Chapter 2). 
 YJ34 is a useful tool for studying RGS function, and in this Chapter, efforts to 
improve its potency with the use of a focused OBOC peptide library to screen for RGS4 
inhibitors is reported. The library was restricted to peptides containing the structural 
elements listed above that have been shown to be required for the function of YJ34. The 
other 5 amino acids were randomized among the 19 natural amino acids (except Cys) to 
afford 2.5 million possible peptide sequences. The library was synthesized and screened 
for RGS4 binding using beads with only one peptide sequence each. However, 
approximately half of the peptides on each bead had an acetyl group, because it was 
important for YJ34 function, and half had a free N-terminus, so that the hits could be 
sequenced by Edman degradation. From this screen, seven peptide sequences that bound 
to RGS4 were identified. Two analogs of peptide 2, 2ad (Ac-Gly-Thr-c[Cys-Phe-Gly-
Thr-Cys]-Trp-NH2, S-S) and 2nd (Gly-Thr-c[Cys-Phe-Gly-Thr-Cys]-Trp-NH2, S-S) are 
novel inhibitors of RGS4. 
 
Materials and Methods: 
 
Materials: Fmoc-protected amino acids and Rink amide resin were purchased 
from Advanced ChemTech. Fmoc protected and acetylated amino acid purity were 
verified by HPLC. Tentagel Resin was purchased from ChemImpex or Rapp-Polymer, 
and Alexa Fluor label from Invitrogen. Peptide synthesis grade chemicals were purchased 




diluted with unlabeled GTP to the desired level of radioactivity. Amylose resin was 
purchased from New England Biolabs and the Ni-NTA resin from Qiagen. 
  
Protein Expression, Purification and Labeling: His6-Gαo (rat), and RGS4Δ18N 
(rat), were expressed and purified according to previous protocols (Lan, et al. 1998, Lan, 
et al. 2000, Lee, et al. 1994, Roman, et al. 2007). Mbp-His6-RGS4Δ51N (human), Mbp-
His6-RGS16 (human) Mbp-His6-RGS19Δ11C (human) Mbp-His6-RGS7 RGS domain 
(human, nucleotides 915-1359), and the mutant Mbp-His6-RGS4Δ51N lacking all seven 
cysteines (called “-7C”) were in Gateway pMAL vectors and were expressed using a 
similar protocol as the RGS4Δ18N construct and purified over an amylose column 
followed by a Ni-NTA column according to the manufacturer’s protocol. In some cases 
this was followed by a size exclusion column as necessary. The mutagenesis was done 
using the “QuickChange Multi Site-Directed Mutagenesis Kit” from Stratagene 
according to the manufacturer’s protocol. David Roman made some of the Gαo and 
RGS4Δ51N used. He produced the -7C mutant, RGS16 and RGS7. Levi Blazer made the 
RGS19. Labeling of RGS4 with succinimide ester fluorophores (Alexa Fluor 568 and 
Alexa Fluor 532) was done according to the manufacturer’s protocol with approximately 
2- to 3-fold excess fluorophores and was done by either David Roman or myself. 
 
OBOC Peptide Library Synthesis: The protocol was based on previous reports 
(Cabilly. 1998, Lam, et al. 1991) using a manual “mix and split” synthesis. TentaGel 
amide resin (10 g of 130 µm sized beads with a substitution level of 300 pmole/bead) was 




polypropylene filter columns. To each column a different Fmoc-protected amino acid 
dissolved in NMP was added; all natural amino acids were used at the random positions 
except for cys. This was followed by a solution with a 3-fold excess HBTU/HOBt plus 
DIEA in NMP and the mixture was shaken for 1 hour. Then the beads were rinsed 
thoroughly in NMP. Unreacted amines on the resin were acetylated with a 20-fold excess 
of acetic anhydride with DIEA and HOBt in NMP. After a negative bromophenol blue 
test, the beads were pooled and treated with 50% piperidine in NMP. The splitting, 
coupling, pooling, and deprotection (but not the acetylation) steps were repeated for the 
randomized positions. For the non-random positions, the resin was not split and Fmoc-
Cys(trt)-OH (positions 3 or 7) or Fmoc-Gly-OH (position 5) was coupled to the whole 
batch. In the final coupling step, a 1:1 mixture of acetylated and Fmoc-protected amino 
acids was used. To remove the side chain protecting groups without cleaving the peptide 
from the resin (based on a control peptide and Cabilly. 1998), all the beads were pooled 
and treated with 50 ml ice-cold 88:5:5:2 TFA:phenol:water:TIPS and shaken for 3 hours. 
(Treatment of test peptides with deprotection conditions resulted in no detectable cleaved 
peptide by HPLC.) After thorough washing (including a wash in 10% DIEA), the resin 
was added to 7.8 L oxidation solution (20% DMSO, 5% Acetic acid, in water pH 6.0 
purged of air with N2) and shaken for 48 hours.  
 
Library Screening: Beads were washed and plated in a single layer (on average 
about 1,500 beads per well) in 96 well plates in buffer (1% BSA in 20 mM Hepes pH 8.0) 
and incubated with 25 nM RGS4Δ18N-Alexa Fluor 568. Wells containing YJ34 on beads 




belonging to Gus Rosania, using an excitation of 532 nm and an emission of 610 nm and 
quantified with the accompanying ImageQuant software. To do this, a 12x8 grid was 
placed over the image such that each grid block contained only one well. Grid blocks 
containing an object with intensity more than 5-10 fold over the most intense object in 
the wells containing YJ34 were collected and pooled. The image was visually inspected 
and any objects that were clearly not beads, such as dust or other debris, were excluded. 
Pooled beads were washed, diluted and re-screened against 10 nM RGS4Δ18N-Alexa 
Fluor 568. The process was repeated until a single bead per well was obtained. The top 
20 most fluorescent beads were then isolated with a needle under a dissecting microscope 
and sent for sequencing by Edman degradation at the Biomedical Research Core 
Facilities at the University of Michigan.   
 
Synthesis of individual Peptides: Soluble peptides (for GAP assays) were 
synthesized by myself or Anjanette Turbiak on cleavable Rink resin and cyclized as 
described previously (Jin, et al. 2004, Roof, et al. 2006, Chapter 2). Peptide purity (at 
least 95%) and solubility were verified by HPLC and correct mass was verified by MS 
analysis (Roof, et al. 2006, Chapter 2). YJ34 and BR2 bead bound controls were 
synthesized by myself on 130 µm Tentagel resin using the same protocol as the library 
except no “mix and split” steps were incorporated. Peptides on beads (for the FACScan 
assay) were synthesized by Katarzyna Sobczyk-Kojiro using a LabMate apparatus 
(Advanced Chem Tech) and cyclized manually using the similar chemistries as for the 




Tentagel resin was used. The deprotection mixture was 83:5:5:5:2 TFA:thioanisole: 
phenol:TIPS and an Ellman test was performed to ensure complete oxidation.  
 
Binding of test peptides: Unreacted 130 µm TentaGel amide resin or resin 
containing YJ34 or BR2 was put into wells of a 96 well plate with 5 mg/well in 0.5 ml 
buffer (1% BSA in 20 mM Hepes pH 8.0) for 1 hour. The supernatant was removed and 
various concentrations of Alexa Fluor 568 labeled RGS4Δ18N were added in 200 µl 
followed by incubation for 15 min. After a wash with 500 µl buffer, fluorescence was 
measured in black Costar 96 well plates in a Victor2 fluorescence plate reader with an 
excitation filter at 560 and an emissions filter at 595. Samples were measured in 
duplicate.  
 
 FACScan Flow Cytometry: Peptide beads (about 5 x 103 per sample for a 
maximum of 5 nmoles peptide) were washed then incubated with 25 nM RGS4Δ51N-
Alexa Fluor 532 in 300 µl for at least 15 min at room temperature under foil. The Becton 
Dickinson FACScan, kindly shared by Kathleen Collens, was gated and the laser 
intensity set in CellQuest such that control beads (acetylated TentaGel resin) were gated 
and had low but measurable fluorescence. No compensation was set. Fluorescence of 
RGS4Δ51N-Alexa Fluor 532 bound to acetylated beads was about ~60 % of YJ34 beads 






RGS-Stimulated GTPase: Single turnover GTP hydrolysis measurements with 
and without RGS were performed as described previously (Roof, et al. 2006, Chapter 2). 
 
Modeling: Peptides were modeled by Ira Pogozheva using Quanta by modifying 
the residues from the Gαi1 switch 1 in the RGS4-Gαi1 (PDB: 1agr) crystal structure 
(Tesmer, et al. 1997). Upon residue substitution and formation of the disulfide bond, 
energy minimization of each peptide with all hydrogen atoms added was performed using 
the Quanta/CHARMm simulation package with dielectric constant (ε)=10 and the 
Adopted-Basis Newton Raphson method (50 steps). To model the peptide-RGS complex, 
each minimized peptide with the hydrogens removed was substituted for the 
corresponding Gαi fragment from the Gαi-RGS4 complex. Images were prepared using 
PyMol for OS X (http://www.pymol.org). 
 
Statistical Analysis: Data are expressed as mean ± S.E.M (or ± S.D for n=2) and 
analyzed by either a t-test (GAP data) or a one-way ANOVA (Victor based test binding 
and FACScan data). A Bonferroni post-test was done on the FACScan data. Significance 




 OBOC Library Design and Screening: It was found in Chapter 2 that some 
features were necessary for activity of YJ34: The N-terminal acetyl group, the C-terminal 
amide, the Gly at position 5, and Cys at positions 3 and 7 with their side chains linked via 




2006, Chapter 2). As seen in Table 3.1, the features necessary for YJ34 function were 
constrained in the library, while the other positions were randomized. All natural amino 
acids except cysteine were used in the other 5 positions to give 2.5 million possible 
sequences. Using 10 g of 130 µm TentaGel beads resulted in approximately 7.9 million 
beads. Thus each sequence would have been on 3 beads in the library on average. In an 
OBOC library, each bead has only one amino acid sequence. However, for this library, 
approximately half of the peptides on each bead were acetylated, since that was necessary 
for the function of YJ34, and half had a free N-terminus, to allow for sequencing by 
Edman degradation. The beads had a substitution level of approximately 300 pmoles, 
resulting in about 150 pmoles of free-amine-containing peptides for sequencing. This was 
found to be sufficient on test peptides.  
Another control included ensuring that YJ34 on beads bound to RGS4 (Figure 
3.1). Although TentaGel resin is known not to be cleavable with TFA treatment (Cabilly. 
1998), it was verified that deprotection conditions did not remove test peptides from resin 
(as discussed in the methods). Tentagel resin was chosen because it has been used 
extensively and has good mechanical stability and has a uniform size. Unfortunately, it 
has green autofluorescence (Olivos, et al. 2003), so a red dye (Alexa Fluor 568) was 
chosen for RGS4 labeling for the bead screen. Other investigators have found non-
specific binding to be problematic with this type of resin (Anna Mapp, personal 
communication). Indeed, high non-specific binding to empty resin was found, but this 
was not observed with resin containing BR2, which is an inactive peptide that mimics the 




To screen the library, the beads were treated with Alexa Fluor 568 labeled 
RGS4Δ18N and imaged in a Typhoon Gel Imager as shown in Figure 3.2. Twenty hits 
(numbered 1-20) were isolated and sequenced by Edman degradation (Appendix A). 
Unfortunately, 6 of the hits (numbers 7, 8, 12, 13, 15 and 20) yielded only partial 
sequences due to inconclusive amino acid assignments by Edman degradation, leaving 14 
fully sequenced hits (hit numbers 1, 2, 3, 4, 5, 6, 9, 10, 11, 14, 16, 17, 18, and 19) for 














Table 3.1: OBOC library design. The key features of YJ34 were constrained in the 
library. The library had the Gly at position 5, the Cys at positions 3 and 7 with a disulfide 
bonds, and a C-terminal amide. The other 5 amino acid positions were randomized such 
that each bead had only one sequence. Half of the peptides on each bead had an acetyl 
group and the other half had a free N-terminus. There were approximately 300 pmoles 

















Figure 3.1: RGS4Δ18N-Alexa Fluor 568 binds YJ34 on beads but not BR2 on beads. 
Binding of RGS4 to beads was measured as described. The experiment was done in 
duplicate. (mean ± S.D., n =2). *p<0.05, **p<0.01, ***p<0.001 compared to no 


























Figure 3.2: Screening of the library. The library was screened as described. The left two 
wells contain YJ34 on beads while the right four wells contain library beads. 
Fluorescence was quantified and represented in arbitrary units by the number below the 








Hit verification: Each of the 14 sequenced hit peptides was resynthesized on 20 
µm TentaGel beads. Since both were present in the library, free N-terminal, disufide 
bridged (nd) and acetylated, disulfide bridged (ad) versions of each sequence were made. 
Interaction with Alexa Fluor 532 labeled RGS4Δ51N was detected in a FACScan Flow 
Cytometer (Figure 3.3). The RGS4Δ51N protein lacking the amphipathic helix in the N-
terminus was used to ensure that the verified hits bound to the RGS domain of RGS4. 
Using 2.5-fold increased binding to RGS4Δ51N compared to YJ34 on beads as a cut-off, 
it was found that some of the initial hits were false positives, but hit numbers 1, 2, 3, 4, 9, 
16, and 19 (Figure 3.3) were verified and were chosen for further evaluation. The hits 
identified were structurally different from each other and our lead compound. Both the 
free N-terminal and the acetylated versions of the verified hits bound RGS4Δ51N. This is 
in contrast to YJ34, where only the acetylated version has activity in the GAP assay 

















YJ34 Ac-VKc[CTGIC]E-NH2, S-S 
hit 1       YNc[CQGEC]E-NH2, S-S 
hit 2        GTc[CFGTC]W-NH2, S-S 
hit 3        LVc[CKGYC]Q-NH2, S-S 
hit 4        KVc[CMGGC]T-NH2, S-S 
hit 9       YWc[CKGLC]K-NH2, S-S 
hit 16        KLc[CHGYC]H-NH2, S-S 
hit 19        KHc[CYGFC]K-NH2, S-S 
 
Table 3.2: The verified hits. Peptides from Figure 3.3 that bind RGS4Δ51N-Alexa Fluor 
532 at least 2.5-fold more than YJ34 are shown. Note that both acetylated, disulfide 
















Figure 3.3: Hit verification. The 14 hits for which complete sequences were obtained 
were resynthesized on beads and tested for binding to RGS4Δ15N-Alexa Fluor 532 as 
described (mean ± S.E.M.(or S.D when n=2), n≥2). *p<0.05, **p<0.01, ***p<0.001 








Peptide activity in GAP assays: Peptides were tested in a single turnover 
GTPase assay at 50 µM except where limited by solubility. Effects on the rate of RGS 
stimulated Gαo GTPase activity was measured in a single turnover assay with purified 
proteins and peptides in solution (Figure 3.4). Hit 16 was not evaluated because of signs 
of aggregation. Only peptides 2nd (the free N-terminal, disulfide bridged hit 2) and 2ad 
(the acetylated, disulfide bridged peptide 2) had statistically significant inhibition of RGS 
activity (48 ± 7 percent inhibition at 50 µM and 30 ± 12 percent inhibition at 25 µM 
respectively). Based on these values, both peptides have an estimated IC50 of about 50 
µM. Other peptides that had some activity included 1nd (33 ± 15 percent inhibition at 50 
µM) and 4nd (33 ± 16 percent inhibition at 50 µM). The activity of hit 2 was investigated 
further (Figure 3.5).  
Linear as well as disulfide bridged versions of peptide 2 (2nl: free N-terminal 
linear and 2al: acetylated linear) were tested in the GAP assay since cyclization yields 
may have been less than 100% in the synthesis of the library leaving some linear peptides 
present on each bead, which may have contributed to the observed fluorescence of the 
bead (Figure 3.5A). Consistent with previous results for YJ34, the linear peptides were 
inactive. RGS selectivity was also investigated. Interestingly, peptides 2ad and 2nd were 
inactive against RGS7, RGS16 and RGS19 (Figure 3.5B). RGS16, like RGS4, is in the 
R4 family, while RGS7 and RGS19 are in different families (R7 and RZ respectively) 
and have lower homology with RGS4. It is worth noting that different concentrations of 
RGS proteins were needed to obtain comparable hydrolysis rates in the absence of 




compared to RGS4 explain the lack of activity, however. It is expected that higher 
concentrations are needed due to either presence of inactive protein (as concentration 
measurements are determined by Bradford assays) or lower intrinsic activity of the RGSs 
on Gαo. In the former case, inactive protein would not affect peptide activity. In the later 
case, it would be expected that, selectivity aside, ability of the peptide to inhibit would 
correlate with RGS activity, which has been equalized by the way the experiment was set 
up (ie. by having different RGS concentrations). Thus it is thought that peptide 2 has 
RGS selectivity. 
 Recently, CCG-4986, a small molecule inhibitor of RGS4 was identified and 
found to interact with RGS4 through cysteine modification on RGS4 (Kimple, et al. 
2007, Roman, et al. 2007, Roman, unpublished observations). For this reason, the activity 
of our original peptide, YJ34 as well as hit 2 was evaluated with an RGS4Δ51N mutant 
lacking all 7 cysteines (-7Cys) (Figure 3.5C). The -7C mutant was inhibited by 2ad, 2nd 
and YJ34. There was no statistically significant difference between the activity on wild 
type and the -7C RGS4Δ51N for 2ad, 2nd or YJ34 (59 ± 4, 27 ± 7, 60 ± 11 percent 







Figure 3.4: Activity of hit peptides in a single turnover GAP assay. A) Representative 
time course. B) Rates were calculated based on the time courses, and percent decrease in 
the rate of RGS stimulated GTP hydrolysis by peptides was measured (mean ± S.E.M., n 







Figure 3.5: Functional activity of peptide 2. A) Disulfide-bridged (2nd and 2ad), but not 
linear (2nl and 2al) peptides inhibit RGS4Δ51N GAP activity. B) Peptides 2nd and 2ad 
are selective for RGS4Δ51N (75-125 nM) over RGS7box (500 nM), RGS16 (1.5 µM) or 
RGS19 (200 nM). C) Activity of 2nd and 2ad on wild type and -7C mutant (200 nM) 
RGS4 (mean ± S.E.M. (or S.D when n=2), n ≥2). *p<0.05, **p<0.01, ***p<0.001 







   
 
Model of 2ad binding. Based on the crystal structure of RGS4 bound to Gαi1 
(Tesmer, et al. 1997), Thr182 of Gαi interacts with several residues in RGS4 including 
Asn88, Asp163 and Leu159. The corresponding residue in YJ34, Thr4, was modeled to 
interact with RGS4 in the same manner. However, there is a Phe at this position in 
peptide 2 and it is unlikely that this bulkier, non-polar side chain interacts with RGS in 
the same manner as the Thr4 side chain of YJ34 (Figure 3.6A). However, if the peptide 
were rotated around the central Gly, then the Thr in position 6 would fit into the pocket 
that Thr182 of switch 1 binds, and the Thr4 of YJ34 is thought to bind. This would also 
position the Phe4 of hit 2 above Tyr84 in RGS4 where Ile185 in switch 1 is (Figure 3.6B). 
These two amino acid interactions are reminiscent of YJ36 (Ac-Val-Lys-c[Cys-Thr-Gly-
Phe-Cys]-Glu-NH2, S-S, Roof, et al. 2006, Chapter 2), which has a Thr at position 4 and a 
Phe at position 6. YJ36 inhibited RGS4 GAP activity nearly 40% at 100 µM (Roof, et al. 
2006, Chapter 2). Thus it is proposed that hit 2 interacts with RGS4 in the switch 1 
binding site in an antiparallel orientation (Figure 3.6B). Also in Chapter 2, peptide GU1, 
(Ac-Val-Lys-[Cys-Thr-Gly-Met-Cys]-Glu-NH2, S-S) with a Met at the Ile position of 
YJ34, inhibited RGS4 22 ± 9 percent. This may indicate that hit 4nd, which inhibited 
RGS4 33 ± 16 percent at 50 µM and with a Met in position 4 and a Gly at position 6, also 
binds in the reverse orientation. It is interesting that ES2, and GU2, the ethylene 
dithioether bridged versions of YJ36, and GU1 respectively, are more active than YJ36 




 (61 ± 11 percent inhibition at 100 µM for GU2 vs. 22 ± 9 at 100 µM for GU1). This 
raises the possibility that increasing the bridge length of 2ad or 2nd might increase 










Figure 3.6: Model of YJ34 and 2ad in the switch 1 binding site of RGS4. Amino acids in 
RGS4 mentioned in the text are in cyan. A) YJ34 is modeled to bind RGS4 the same way 









 A focused OBOC peptide library was screened for binding to a fluorescently 
labeled RGS4Δ18N. Twenty hits were selected and sequenced, yielding 14 complete 
sequences that were resynthesized. The hit peptides were verified for binding to 
RGS4Δ51N, and seven were chosen for further evaluation. From these seven hits, one 
peptide sequence (in both free amide and acetylated form) was found to inhibit 
RGS4Δ51N GAP activity in the single turnover GAP assay. Thus the focused library 
approach was a success; hit peptides were identified that appear to have the desired mode 
of binding to RGS4, and the desired activity. 
 As shown in Figure 3.3, both the free N-terminal and the acetylated versions of 
most verified hit peptides bind RGS4Δ51N, with hit 9 being the exception. This is in 
contrast to the YJ34 series where only the acetylated version inhibits RGS4 activity 
(Roof, et al. 2006, Chapter 2). It is possible that some of these peptides do not interact 
with RGS4 the same way YJ34 does. In fact, the observation that many of them do not 
have an effect on GAP activity would suggest that this is the case, and that these analogs 
interact with RGS in alternate ways. RGS4 has been shown to have an allosteric site 
where PIP3 and calmodulin are known to bind (Ishii, et al. 2005). Calmodulin binding 
alone does not affect GAP activity, but blocks the inhibition by PIP3 (Ishii, et al. 2005). It 
is therefore possible that some of the peptides isolated in the library bind RGS4 at this 
site without affecting RGS4 GAP activity. Alternatively, these peptides may bind other, 
perhaps as of yet unidentified, protein-protein interaction sites. The fact that the 
sequences obtained in the library are so divergent from the sequence of YJ34 also 




In fact, it is hard to find any clear clusters based on the homology of the varied positions. 
It is therefore speculated that RGS4 may have several peptide (and therefore endogenous 
protein or lipid) binding sites. The physiological significance of these sites on RGS4 
would be an interesting topic for future work. 
 As in the YJ34 series, linear versions of hit 2 are inactive. Also, as in the YJ34 
series, hit 2 is most active on RGS4. It is thought that CCG-4986 inhibits through 
cysteine modification (Kimple, et al. 2007, Roman, et al. 2007, Roman, unpublished 
observation). Because of the apparent sensitivity of RGS4 to redox manipulations, and 
because of cysteines in the peptides, it was examined whether a similar mechanism might 
exist here. Hence, peptides 2ad, 2nd and YJ34 were tested against the -7C mutant. The 
observation that none of the peptides differentiated between wild type and the -7C mutant 
supports a mechanism of action like that of YJ34, rather than via a covalent interaction 
with RGS4 cysteines. 
 The side chain order and ring size of 2ad and 2nd are the same as YJ36 within 
the cycle. However, the backbone is different. The fact that both have activity opens up 
the possibility for non-peptide analogs such as β-amino acid and peptoid analogs. 
Peptidomimetics have the advantage of not being protease substrates and increased 
stability makes them more useful in cells and in vivo (Fear, et al. 2007). Thus 
peptidomimetics are an interesting avenue for future investigations. 
Future directions could also include verification of the peptide 2-RGS4 model, 
which could be done by modifying either the peptide or the RGS4. It could be 
hypothesized that substitution of Tyr84 by something charged would disrupt 2nd and 2ad 




important for interactions with the Gα subunit and RGS GAP activity (Natochin, et al. 
1998), would disrupt peptide activity. Also, based on the YJ36 data in Chapter 2 and in 
Roof et al (2006), it could be hypothesized that an ethylene bridged peptide would be 
more potent than a disulfide bridged version of hit 2.  
 Thus the focused library was a success; new peptides were identified which are 
modeled to bind in the YJ34 binding site of RGS4, and have YJ34-like activities. And 
although the potency or YJ34 was not improved on, structural insights were gained, 
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As discussed in Chapter 1, RGS proteins are interesting therapeutic targets. Also 
as discussed in Chapter 1 and Chapter 3, a focused OBOC library was utilized to screen 
for RGS4 inhibitors. Here the observations made in Chapter 3 are extended to include a 
second hit from the library that did not have significantly inhibit RGS4 GAP activity, but 
disrupts RGS4-Gαo binding. Thus the focused library approach had mixed success as one 
peptide, peptide 2, has the intended action and is modeled to bind the intended site on 
RGS4, while another peptide, peptide 9, appears to have a different mechanism.  
 
Materials and Methods: 
 
Materials: Fmoc-protected amino acids and Rink amide resin were purchased 
from Advanced ChemTech. Peptide synthesis grade chemicals were purchased from 





Protein Expression, Purification and Labeling Proteins were expressed, 
purified and labeled as described in Chapters 2 and 3. Most of the mutagenesis was done 
by David Roman using the “QuickChange Multi Site-Directed Mutagenesis Kit” from 
Stratagene according to the manufacturer’s protocol. To cleave RGS4 form the Mbp-His6 
construct (for MS analysis), Mbp-His6-RGS4Δ51N was treated with 15% Mbp-His6-Tev 
protease S219V that was prepared with the help of David Roman (Lucast, et al. 2001) for 
22 hours at 4oC and purified over a Ni-NTA column.  
 
Peptide Synthesis: Soluble peptides (for GAP assays) were synthesized by 
myself or Anjanette Turbiak on cleavable Rink resin and cyclized as described previously 
(Jin, et al. 2004, Roof, et al. 2006, Chapter 2, Chapter 3). Peptide purity (at least 95%) 
and solubility were verified by HPLC and correct mass was verified by MS analysis 
(Roof, et al. 2006, Chapter 2, Chapter 3).  
 
FCPIA (Flow Cytometry Protein Interaction Assay): The FCPIA was 
performed as previously published (Roman, et al. 2007). For the peptide wash 
experiments, biotin-RGS on avidin beads was treated with peptide for 10 min and then 
washed three times. The beads were then added to the Gαo-Alexa Fluor 532 as described 
in Roman et al (2007). For the peptide pretreatment experiment, the 10 min peptide 
incubation was followed by addition of a second peptide or DMSO for 15 min before the 
wash. The final concentrations are stated in the Figure legends. Samuel Clements did the 





Mass Spectrometry: Total mass MS of 5 µM RGS4Δ51N was analyzed on a 
MicroMX MALDI MS instrument in positive ion mode with an accuracy of ± 0.1% after 
pretreatment with DMSO or 250 µM 9nd. Alternatively, samples cut from a gel were 
treated with 1.5 µg trypsin in 100 mM ammonium bicarbonate pH 8.0-8.5 in enough 
buffer to cover the gel piece. This was incubated overnight at 37 oC, extracted with 50% 
Acetonitrile/0.1% aqueous TFA, and then subject to LC-MS/MS on a Q-TOF Premier 
Mass Spectrometer. Both were performed at the Biomedical Research Core Facilities at 
the University of Michigan. 
 
Results and Discussion: 
 
 The hit peptides reported in Chapter 3 were tested in the FCPIA assay. This 
measures the interaction between biotinylated RGS4 on avidin beads with Alexa Fluor 
532 labeled Gαo in a Luminex flow cytometer (Roman, et al. 2007). Peptides were tested 
at 50 µM except where limited by solubility (Table 4.1). Peptides 2nd, 9nd, 9ad, 19nd 
and 19ad (Table 4.1) all had statistically significant inhibition of the RGS4-Gαo 
interaction, with hit 9 being the most active (80 ± 5 and 37 ± 3 percent inhibition for 9nd 
and 9ad, respectively) (Figure 4.1). It is interesting to note that YJ34, a known inhibitor 
of RGS GAP activity (Jameson, et al. 2005, Jin, et al. 2004, Roof, et al. 2006), failed to 
disrupt the RGS4-Gαo interaction (-17 ± 4 percent inhibition), as will be discussed 













Figure 4.1: Hit peptides in the FCPIA. Hit peptides from Chapter 3 were tested at 50 µM 
unless otherwise indicated for ability to disrupt the RGS4-Gαo interaction as described 
using 25 nM Gαo-Alexa Fluor-532 and 5 nM wild type RGS4Δ51N-biotin (mean ± 












Name Sequence cyclization Buffer Solubility 
(µM) 
ALogP  % Inhibition of 
RGS4-Gαo 
YJ34 Ac-VKCTGICE-NH2 S-S 80 -2.58 -17 ± 4 (40 µM) 
1nd YNCQGECK-NH2 S-S ≥ 420 -2.8 2 ± 4 
1ad Ac-YNCQGECK-NH2 S-S 123 -2.37 14 ± 6 
2nd GTCFGTCW-NH2 S-S 464 -0.37 19 ±  3** 
2ad Ac-GTCFGTCW-NH2 S-S 30 0.08 10 ± 4 (10 µM) 
3nd LVCKGYCQ-NH2 S-S ≥ 470 -0.37 12 ± 2 
3ad Ac-LVCKGYCQ-NH2 S-S 427 0.17 10 ± 3 
4nd KVCMGGCT-NH2 S-S ≥ 470 -2.02 4 ± 3 
4ad Ac-KVCMGGCT-NH2 S-S 459 -2.09 9 ± 6 
9nl YWCKGLCK-NH2 Linear 465 1.46 -1 ± 10 
9al Ac-YWCKGLCK-NH2 Linear 460 1.66 -2 ± 4 
9nd YWCKGLCK-NH2 S-S 463 0.48 80 ±  5*** 
9ad Ac-YWCKGLCK-NH2 S-S 464 1.04 37 ±  3*** 
9nm YWCKGLCK-NH2 S-me-S ≥ 470 0.53 3 ± 0.1 (100 µM) 
19nd KHCYGFCY-NH2 S-S low  0.94 23 ±  15 (25 µM) * 
19ad Ac-KHCYGFCY-NH2 S-S 421 1.24 27 ±  4*** 
 
Table 4.1: Hit peptide names, sequences and physical properties. Solubility in buffer was 
determined experimentally by HPLC. ALogP calculations are from www.vcclab.org, 
(Tetko, et al. 2005). Percent inhibition (50 µM unless otherwise stated) is from Figure 
4.1, (mean ± S.E.M., n≥3) *p<0.05, **p<0.01, ***p<0.001 compared to no peptide. 








 In Figure 4.2A, it is shown that the IC50 values for 9nd are 28 µM, 43 µM, 66 
µM, 145 µM and 175 µM on RGS4, RGS8, RGS16, RGS19 and RGS7 respectively 
(logIC50 of -4.56 ± 0.02, -4.36 ± 0.02, -4.18 ± 0.03, -3.84 ± 0.05 and -3.76 ± 0.08 for 
RGS4, RGS8, RGS16, RGS19 and RGS7 respectively). RGS4, RGS8 and RGS16 are all 
in the same family (R4) and are the most homologous to RGS4. RGS19 and RGS7 are in 
the RZ and R7 families respectively. Linear as well as bridged versions of peptide 9 were 
tested since cyclization yields would most likely have been less then 100% in the 
synthesis of the library leaving some linear peptides present on each bead. The linear 
peptides were found to be inactive (-1 ± 10 and -2 ± 4 percent inhibition for 9nl and 9al 
respectively) (Figure 4.2C). This may be due to a lack of structural rigidity necessary for 
the correct interaction of the peptide with the RGS protein. 
 As discussed in Chapter 3, a small molecule inhibitor of RGS4 was identified in a 
FCPIA screen and found to interact with RGS4 through cysteine modification (Kimple, et 
al. 2007, Roman, et al. 2007, Roman, personal communication). For this reason it was 
desirable to determine if peptide 9nd acts in a similar manner. It was found that when 
biotin-RGS4 on avidin beads was treated with 9nd and then washed, the peptide still 
inhibited RGS4-Gαo interactions (75 ± 11 percent). Inclusion of DTT in the wash buffer 
significantly decreased 9nd activity (15 ± 4 percent inhibition) (Figure 4.3A). This 
suggests that the peptide may bind irreversibly through a disulfide bridge. To further 
investigate this possibility, a methylene dithioether bridged peptide, 9nm (Table 4.1), 
was synthesized and found to be inactive (3 ± 0.1 percent inhibition) (Figure 4.3A). Since 
the methylene dithioether bridged peptide would be incapable of forming a disulfide 




that this bridge may be necessary for its function. Although it is also possible that the 
structural change from the increased bridge length was responsible for the loss of activity 
of 9nm compared to 9nd. The same pattern was seen with RGS8. The activity of 9nd 
was lost with washing only if DTT was included in the buffer and 9nm had only a small 
effect on RGS8 activity (64 ± 2, 50 ± 3, 10 ± 3, and 18 ± 1 percent inhibition for 9nd no 
wash, 9nd wash, 9nd DTT wash and 9nm respectively) (Figure 4.3B). Although YJ34 
does not affect the interaction of RGS4 with Gαo, it was reasoned that if 9nd was 
working by binding to the switch 1 binding site of RGS4, its activity could be blocked 
with YJ34. In Figure 4.3C, YJ34 failed to block the activity of 9nd suggesting that 
binding to the YJ34 site on RGS4 is not necessary for 9nd function, or that the covalent 
binder can compete with YJ34 for binding. Peptide 9mn also failed to block 9nd binding, 









Figure 4.2: Characterization of hit 9. A and B) Dose response curves for 9nd in the 
FCPIA with different RGS proteins (RGS Family), (mean ± S.E.M., n=3) *p<0.05, 
**p<0.01, ***p<0.001 compared to RGS4 at the same 9nd concentration. C) Peptides 
were tested at 50 µM as in Figure 4.1, (mean ± S.E.M., n≥3) *p<0.05, **p<0.01, 














Figure 4.3: Irreversibility experiments. RGS-biotin on avidin beads was treated with 9nd 
(100 µM) or 9nm (100 µM) and then washed in buffer (with or without 1 mM DTT) or 
not washed and put in the FCPIA using RGS4Δ51N (A) or RGS8 (B) (mean ± S.E.M., 
n≥2) *p<0.05, **p<0.01, ***p<0.001 compared to no peptide (100%); #p<0.05, 
##p<0.01, ###p<0.001 compared to 9nd no wash. C) RGS4Δ51N-biotin on avidin beads 
was treated with DMSO or peptide (20 µM YJ34 or 50 µM 9nm). After the pre-
incubation, the samples were treated with DMSO or 9nd (50 µM) (mean ± S.E.M., n=3) 
*p<0.05, **p<0.01, ***p<0.001 compared RGS4 treated with DMSO then DMSO 
(100%); #p<0.05, ##p<0.01, ###p<0.001 compared to RGS4 treated with DMSO then 











Figure 4.4: MS analysis of RGS4 with and without 9nd pretreatment. RGS4Δ51N was 
cleaved from the mbpHis6 construct and subject to MALDI MS after pretreatment with 
DMSO (A) or 9nd  (250 µM) (B). Both spectra show the region between 4,000 and 
30,000 m/z and have the peak at 18158.8 or 18158.2 m/z for A and B respectively, which 
corresponds to the RGS4 protein (black arrows). The spectrum in B also has a peak at 
19158 m/z that corresponds to a peptide adduct (grey arrows). There is a very small peak 
at 20157.9 that may correspond to 2 peptide adducts (grey arrows). The inset is a blow-up 











Figure 4.5: RGS alignment. A) The structure of the RGS4 domain (Tesmer, et al. 1997) 
with the cysteines highlighted. B) An alignment of the RGS proteins used in Figure 4.3 
compared to the RGS4Δ51N construct. The RGS proteins are listed in order of inhibition 
by 9nd. The red residues are conserved and the blue are not. The stared residues are 








The formation of a covalent adduct between 9nd and RGS4 was confirmed with 
MS analysis (Figure 4.4). An adduct to the protein (following Tev-protease cleavage 
from the MbpHis6 construct) that is consistent with the mass of 9nd binding through a 
disulfide bridge was observed by MS (observed: Δ999.2 ± 1; expected: Δ998.5). No such 
adduct was observed with DMSO treated RGS4Δ51N. There is also a small peak that 
may be a two peptide adduct (observed: Δ 1999.1 ± 2; expected Δ1997.0). 
 Since 9nd forms an irreversible, DTT-sensitive bond with RGS, it was suspected 
that it binds covalently to a cysteine in the protein. Indeed, removal of all 7 cysteines 
(termed the “-7C” mutant) from RGS4Δ51N abolished 9nd activity (logIC50 of -3.24 ± 
0.14 for -7C vs. -4.36 ± 0.02 for wt) (Figure 4.6, Table 4.2). In Figure 4.5, the RGS 
proteins tested in Figure 4.2A are aligned with the N-terminal truncated RGS4 used in 
these studies. It was hypothesized that Cys95 or Cys148 in RGS4 was involved in 9nd 
activity because they are conserved with RGS8 and RGS16, which are also inhibited by 
9nd. However, neither the C95A nor the C148A mutations diminished 9nd activity  
(logIC50 -4.71 ± 0.0.5 and -4.27 ± 0.05 for C95A and C148A respectively) (Figure 4.6A, 
Table 4.2). All mutants bound Gαo in an AMF-dependent manner, although some had 
decreased affinity compared to wild type (Table 4.2). With the assumption that 9nd 
would have to bind within the RGS domain to inhibit Gαo binding, C71A and C132A 
mutations were also tested. The C71A mutation did not affect 9nd activity (logIC50 -4.34 
± 0.06). The C132A mutation did decrease 9nd activity, but only partially (logIC50 -3.86 
± 0.07) (Figure 4.6B, Table 4.2). Thus no single cysteine within the RGS domain is 




In an alternative approach, cysteines were added back to the -7C mutant to 
determine whether 9nd activity could be restored. No single A to C mutation within the 
RGS domain of the -7C mutant restored 9nd activity (Figure 4.6C, Figure 4.6D, Table 
4.2). This suggests that either 9nd can inhibit RGS4 by binding to any one of multiple 
cysteines, or that its actions are through a cysteine in the C-terminus. To evaluate the 
later possibility, mutants lacking all cysteines in either the RGS domain or the C-terminus 
were tested. It was found that the C-terminal cysteines were not involved in 9nd activity 
(logIC50 -4.5 ± 0.2), but that removal of all cysteines from the RGS domain only partially 
blocked 9nd activity (logIC50 -3.8 ± 0.2) (Figure 4.6E, Table 4.2). These observations 
suggest that 9nd has a complex mechanism, as no single cysteine is either necessary or 
sufficient for its actions. Thus it is concluded that 9nd is a non-selective cysteine 
modifier. This would suggest that RGS4 is more sensitive to covalent redox 
manipulations then the other RGS proteins tested. 
 MS was also used in attempt to identify important cysteines for the activity of 
9nd. Following Tev-protease cleavage from the MbpHis6 construct, RGS4Δ51N was 
treated with DMSO or 9nd and subjected to trypsin digest. The fragments were analyzed 
by LC-MS/MS analysis. However, no fragments with an adduct could be identified (data 
not shown). It is suspected that if 9nd were interacting with multiple cysteines in RGS4, 










Figure 4.6: Dose curves of 9nd on various RGS4Δ51N cysteine mutants. Various 
concentrations of 9nd were tested for disruption of the C95A (5 nM), or C148A (5nM) 
(A), C71A (5nM) or C148A (5nM) (B), A95C in the -7C (5nM), or A132C in the -7C 
(5nM) (C), A71C in the -7C (5nM), or A148C in the -7C (5nM) (D) or the mutant with 
no cysteines in the domain (20 nM) or the C-terminus (20 nM) (E) RGS4Δ51N-Gαo 














Mutant Gαo affinity (nM) 9nd logIC50 (M) 
wild type 11.6 ± 1.4 -4.36 ± 0.03### 
C95A 8.17 ± 1.5 -4.71 ± 0.05### 
C148A 6.84 ± 1 -4.27 ± 0.05# 
C71A 12.2 ± 1.8 -4.34 ± 0.06## 
C132A 7.9 ± 3.1 -3.86 ± 0.07 
-7C 8.3 ± 1 -3.24 ± 0.14*** 
A95C, -7C 12 ± 2 -3.58 ± 0.09** 
A148C, -7C 5.7 ± 0.2 -3.51 ± 0.09** 
A71C, -7C 9.2 ± 2 -3.20 ± 0.13** 
A132C, -7C 12.5 ± 1 -3.41 ± 0.09** 
no Cys in RGS domain 3.9 ± 0.8 -3.80 ± 0.06* 
no Cys in C-terminus 5.0 ± 0.7 -4.39 ± 0.07## 
 
 
Table 4.2: Mutant RGS4Δ51N Gαo affinities and 9nd logIC50s. Gαo affinities were 
calculated in the FCPIA as described (Roman, et al. 2007) and logIC50 data is from 
Figure 4.5. (mean ± S.E.M., n≥3) *p<0.05, **p<0.01, ***p<0.001 compared to wild type 












 Here the identification and characterization of a peptide RGS4 inhibitor with a 
novel, yet unknown, mechanism is reported. This peptide, 9nd, binds RGS proteins 
covalently through a disulfide bridge to random cysteines. This peptide raises some 
interesting points regarding the focused screen discussed in Chapter 3. First, it is 
interesting that although the library was focused to include features necessary for YJ34 
activity, a peptide was isolated that clearly works through a different mechanism. Thus 
there was mixed success with the focused approach. The library was biased towards 
peptides that would have the same mechanism as the lead compound. However, this bias 
is by no means a guarantee; there is no reason to suspect that a peptide like hit 2 would 
have been found from a completely random library. 
 Another interesting observation is that RGS4 is preferentially inhibited by the 
cysteine modifier peptide over other RGS proteins. This could be because the peptide is 
selective for RGS4, or because RGS4 is particularly susceptible to cysteine modification. 
This latter possibility is supported by the observation that a small molecule inhibitor of 
RGS4, CCG-4986, that was identified in an FCPIA screen appears to inhibit RGS4 
through covalent modification of cysteines while having no activity against RGS8 
(Kimple, et al. 2007, Roman, et al. 2007, Roman, unpublished observation). Also, RGS4 
is more sensitive to inhibition with N-ethylmaleimide, (a cysteine modifier) then RGS8 
(David Roman, personal communication). Unlike 9nd, CCG-4986 appears to selectively 
modify 1 or 2 cysteines in the RGS4 (Roman, et al. 2007, Roman, unpublished 




compared to 9nd. In future efforts, it may be possible to exploit this susceptibility of 
RGS4 to cysteine modification if a cycteine reactive peptide were also a selective, high 
affinity binder to a particular pocket on the RGS. 
 A third observation is that there is a correlation between peptide logP and activity 
in the FCPIA (Table 4.1). The order of activity in the FCPIA is hit 9>hit 19>hit 2> the 
rest of the hits, while the order of hydrophobicity is hit 19>hit 9>hit 3>hit 2> the rest of 
the hits. Given the considerable error in computational logP calculations (Thompson, et 
al. 2006), it is reasonable to suggest that the most hydrophobic peptides have the most 
activity in general. This also tells us something about RGS4. These data suggest that 
RGS4 binding sites have hydrophobic surfaces and investigators should be mindful of 
this when choosing libraries for future screens. 
 Although attempts to improve on existing RGS4 inhibitors failed, it is hoped that 
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 Inhibition of protein-protein interactions (PPI) is particularly challenging. Unlike 
enzymes and receptors that have well defined pockets, protein-protein interfaces tend to 
be large and flat (Whitty & Kumaravel. 2006). Because of this, many PPI have been 
declared “non-amenable” to inhibition based on computational measurements (Fry & 
Vassilev. 2005). In fact, the RGS4-Gαo interaction falls in this category (David Fry, 
personal communication).  
However, some “hot spots” have been found in protein-protein interfaces, 
involving a limited number of residues that are responsible for the majority of the 
interaction energy. Others have taken advantage of this to successfully create peptide and 
small molecule inhibitors of PPIs. For example, Thanos et al. found a small molecule that 
was capable of binding to interleukin-2 in such a way that prevented its receptor 
interaction. Even though it was much smaller, the molecule was able to target the same 
critical “hot spots” that the receptor contacts (Thanos, et al. 2006). Another example is 
the screen done by the Smrcka lab for peptide inhibitors of Gβγ. Although the hit 
sequences were diverse, they all bound the same site on the protein, and one of the 





Another encouraging point is that computational approaches such as those used in 
Fry and Vassilev (2005) are based on rigid structures of proteins. Others have shown that 
protein interfaces are adaptable and in multiple cases small molecules bind in induced 
pockets that are not observed in the structures of the protein alone or in complex with its 
natural protein binding partner (Wells & McClendon. 2007 and references therein). Thus 
these interactions could not be rationally predicted in spite of the existence of a structure 
of the target protein and could only come from experimental screening. Hence, although 
this screen of RGS4 inhibitors was an ambitious project, there are ample precedents for 
success.  
 A relatively uncommon approach for HTS was taken with the focused library. 
Although there are examples of those who have used the focused approach (Chang, et al. 
2008, Laird & Blake. 2004, Whiting, et al. 2006), screening of a random library is far 
more common. Placing limitations on the structures screened can increase the chances of 
identifying an inhibitor with the desired mechanism of action, but it can also prevent 
identification of potentially more interesting or more potent compounds that act with 
unique mechanisms. In retrospect, it can also be speculated that the library was not 
constrained enough as peptides were found that clearly work through different 
mechanisms than the lead. On the other hand, no peptides were found that were more 
potent than the lead, so it could be argued that a more random screen would have been 
more appropriate. Attempts to identify small molecule inhibitors of the RGS-Gαo 
interaction are underway in the Neubig lab using libraries containing more chemical 




 One potential reason that so many peptides were identified that were not as 
effective as YJ34 is the fact that 4 versions of each sequence were on each bead in the 
library (acetylated and free N-terminal, disulfide and linear). The expectation when the 
library was designed was that only the acetylated disulfide bridged peptide would have 
activity, and the free N-terminal and linear peptides would contribute nothing to the RGS 
interaction, since only the acetylated disulfide bridged version of YJ34 inhibits RGS4 
GAP activity (Jin et al, 2004, Roof et al, 2006, Chapter 2). This hypothesis was based on 
the assumption that many hit peptides would have a YJ34-like mechanism, as the library 
was designed. However, it was found that for most of the peptides, if one version 
displayed significant binding capacity to RGS4 in the FACScan assay, all four did 
(Appendix B). A possible explanation for this observation is that if all four versions of a 
sequence are capable of binding RGS4, then the library bead containing that sequence has 
the potential to be much more fluorescent than if only one version binds. Hence, it 
appears that sequences were inadvertently selected for based on the ability of all four 
versions to contribute to the RGS4 interaction, which, based on YJ34 analog data in 
Chapter 2, should be incompatible with a YJ34-like mode of binding. Thus it is suspected 
that these peptides do not bind RGS4 the way YJ34 binds and this screen may have 
actually selected against peptides with a YJ34-like mechanism. This is in contrast to the 
intended library bias. These competing mechanisms may have hurt the chances of 
identifying more potent RGS4 inhibitors.  
In the single example of a verified hit peptide that inhibits RGS4 GAP activity, it 
is suspected that the peptide binds in the reverse orientation compared to YJ34 and the 




the peptide away from the RGS4 protein. One could speculate that this orientation and 
not the YJ34-like orientation is compatible with the free N-terminal peptide binding to 
RGS4. Hence beads with both free N-terminal and acetylated peptides would have 
increased binding to RGS4 if they bound in the reverse orientation compared to peptides 
binding in the YJ34-like orientation. Had the screen been performed using only 
acetylated peptides, perhaps the identified hits would bind in the YJ34 orientation. In that 
scenario, another method for identifying hit sequences would have to be employed. 
Sophisticated “topically segregated” tags have been used in the past by others with 
OBOC libraries (Hwang, et al. 2004, Liu, et al. 2002, Wang, et al. 2004). Such an 
approach could be used should an OBOC library be screened in the future. 
 Several hit peptides were identified that bound RGS4 in the FACScan assay that 
did not inhibit RGS4 activity in the GAP or FCPIA assays. Aside from the interesting 
observation that the focused library resulted in several hits without the predicted 
mechanism of action (and therefore, presumably, without the predicted mode of binding 
to RGS4), this also raised the question of where on RGS4 the peptides were binding. As 
discussed in chapter 4, there are known allosteric binding sites on the RGS domain of 
RGS4. There is also the interesting possibility that these peptides bind unidentified 
protein-protein interaction sites on RGS4. As discussed in Chapter 1, RGS4 has 
physiological roles beyond being a GAP protein, and these peptides could be used as 
tools for identifying other RGS4 binding partners within a cell. It would be an exciting 
project for a future student to see what can be immunoprecipitated out of cell lysates with 




have a new PPI and an inhibitor of it. This student would immediately have a tool for 
evaluating the function of the newly discovered interacting proteins. 
 There appears to be disconnects between peptide activity in the FACS scan assay, 
the GAP assay and the FCPIA assay. It is easy to imagine peptides binding to RGS4 but 
not inhibiting its function. These peptides would bind RGS4 in the FACScan assay but 
not inhibit RGS4 activity in the GAP or FCPIA assays. In fact, peptide 3nd (Leu-Val-
c[Cys-Lys-Gly-Tyr-Cys]-Gln-NH2, S-S) binding to RGS4 has been confirmed in an assay 
that measures the change in the intrinsic fluorescence of unlabeled RGS4Δ18N with 
peptide binding (Appendix C). Peptide 3nd has a Kd of 55 ± 3 nM in this assay, but does 
not inhibit RGS4 activity in the GAP or FCPIA activity (Chapter 3 and Chapter 4).  
The discrepancy between peptide activity in the FCPIA and the GAP assays is 
harder to explain. It is possible that a peptide could block the activity of RGS4 on Gαo 
without disrupting the binding of RGS4 to Gαo. This may be why peptide 2 is so much 
more active at inhibiting RGS4 in the GAP assay than in the FCPIA assay. But how 
could a peptide block the Gαo interaction without impairing GAP activity of RGS4? The 
answer might have to do with differences in the temperatures of the experiments (4o C for 
the GAP assay and 25 o for the FCPIA, as described in Chapter 2 and Chapter 4). There 
may also be a difference in the structure of RGS4 bound to AMF (AlCl3, MgCl2, NaF and 
GDP, a transition state mimic) activated Gαo (as is bound to RGS4 in the FCPIA assay) 
compared to GTP activated Gαo (as is bound to RGS4 in the GAP assay). The peptide 
that inhibited RGS4 the most in the FCPIA, 9nd, did inhibit RGS4 in the GAP assay, 




statistical significance. This may suggest subtle differences in assay conditions, and not a 
fundamental flaw in the assay or the peptide is responsible for the disparity.  
 Other observations from this screening experience that may be helpful in the 
future have to do with the physical properties of RGS4. The Neubig lab has now 
identified both a peptide and at least one small molecule inhibitor of RGS4 that binds 
irreversibly through cysteine modification (Chapter 4, David Roman, personal 
communication, Kimple, et al. 2007, Roman, et al. 2007). As discussed in Chapter 4, 
RGS4 appears to be particularly sensitive to cysteine modifications. Whether or not there 
are physiological implications of this phenomenon is unknown. The -7C RGS4Δ51N has 
both GAP and FCPIA activity. But as cysteines are important for palmitoylation 
(Srinivasa, et al. 1998) one could speculate that this modification may play a role in 
RGS4 actions or regulation in vivo. Regardless, care needs to be taken when screening 
against RGS4 (or other RGSs) in the future. In fact, the Neubig lab is currently screening 
against the -7C RGS4Δ51N mutant. 
 A second observation regarding the physical properties of RGS4 that may be 
useful in future screens, is the observation that there appears to be a correlation between 
hydrophobicity of the peptides and the activity in the FCPIA. It is tempting to speculate 
that Van de Waals interactions between RGS4 and Gαo are more important than non-
hydrophobic interactions. However, there is no data to suggest that 9nd is binding to the 
Gαo interface of RGS4. This may reflect an overall hydrophobicity of RGS4, or it could 
mean that there are hydrophobic allosteric sites on RGS4. What this means for RGS 




future screens may benefit from the inclusions of hydrophobic compounds, as long as the 
hydrophobicity does not preclude in vivo usefulness.  
 In conclusion, overall, this focused library approach was a success, but there are 
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Appendix A: Complete List of Hit-Bead Sequencing Results 
 
hit 1 Tyr-Asn-Cys-Gln-Gly-Glu-Cys-Lys 
hit 2 Gly-Thr-Cys-Phe-Gly-Thr-Cys-Trp 
hit 3 Leu-Val-Cys-Lys-Gly-Tyr-Cys-Gln 
hit 4 Lys-Val-Cys-Met-Gly-Gly-Cys-Thr 
hit 5 Lys-Trp-Cys-Ala-Gly-Met-Cys-Met 
hit 6 Phe-Pro-Cys-Leu-Gly-Ile-Cys-Tyr 
hit 7 ___-Asn-Cys-Try-Gly-Phe-Cys-Lys 
hit 8 ___-Phe-Cys-Phe-Gly-Asn-Cys-Trp 
hit 9 Tyr-Trp-Cys-Lys-Gly-Leu-Cys-Lys 
hit 10 Ser-Val-Cys-Phe-Gly-Leu-Cys-Tyr 
hit 11 Ile-Lys-Cys-Arg-Gly-Ile-Cys-Ser 
hit 12 Gly-Asn-Cys-Gln-Gly-Val-Cys-___ 
hit 13 Pro-Arg-Cys-Leu-Gly-___-Cys-___ 
hit 14 Val-Phe-Cys-Ala-Gly-Ala-Cys-Arg 




hit 16 Lys-Leu-Cys-His-Gly-Tyr-Cys-His 
hit 17 Pro-Arg-Cys-Leu-Gly-Ala-Cys-Arg 
hit 18 Trp-Ala-Cys-Arg-Gly-Val-Cys-Tyr 
hit 19 Lys-His-Cys-Tyr-Gly-Phe-Cys-Tyr 
hit 20 Val-Ile-Cys-Tyr-Gly-Gln-Cys-Gly 
 
Hit peptide-beads were sent for sequencing by Edman degradation at the 
University of Michigan biomedical research core facilities. It should be noted that no 
sequence data can be obtained for cysteines without prior derivatization. Hence, when no 
amino acid assignments were obtained at positions 3 and 7, they were designated to be 
cysteines because of the way the library was synthesized (see Chapter 3). C-terminal 
modifications and cyclization status also cannot be determined with Edman degradation, 
but all hits should have had a C-terminal amide because of the type of resin used in the 











All four versions (nd: free N-terminal, disulfide bridged; ad: acetylated, disulfide 
bridged; nl: free N-terminal, linear; al: acetylated, linear) of the 14 hits for which 
complete sequences were obtained were resynthesized on beads and tested for binding to 
RGS4Δ15N-Alexa Fluor-532 as described in Chapter 3 (mean ± S.E.M. (S.D. when n=2), 

















The intrinsic fluorescence of 200 nM unlabeled (no Mbp, His6 or fluorophores, 
prepared as described in Roman et al (2007)) RGS4Δ18N was measured in 600 µl buffer 
A (filtered 20 mM Hepes, 100 mM NaCl, pH 8.0, at room temperature) in a 10x2 quartz 
cuvette. A Photon Technology International AlphaScan Spectrofluorometer with 4 nm 
slits was used with an excitation wavelength of 285 nm and an emission of 340 nM. 
Increasing concentrations of 3nd (from a 6 µM stock in buffer A with 0.7% DMSO) was 
added. The change in fluorescence seen with addition of the same amount of peptide to 
buffer (with no RGS) was subtracted from each point. For each experiment, the average 




fluorescence with peptide addition. B) The average of three experiments normalized and 
inverted. The data was analyzed using a one fit binding curve with the Bmax constrained 
to 100% using Graphpad Prism. From this the Kd was calculated to be 55 ± 3 nM. 














Name Hit# Sequence Cyclization FW Solubility 
(µM in buffer) 
YJ34  - Ac-VKCTGICE-NH2 S-S 1005 80 
BR14 Hit #1 YNCQGECK-NH2 Linear 1286 364 
BR15 Hit #1 Ac-YNCQGECK-NH2 Linear 1328 ≥ 470 
BR24 Hit #1 YNCQGECK-NH2 S-S 1284 ≥ 420 
BR25 Hit #1 Ac-YNCQGECK-NH2 S-S 1326 123 
BR20 Hit #2 GTCFGTCW-NH2 Linear 873 356 
BR21 Hit #2 Ac-GTCFGTCW-NH2 Linear 916 237 
AJTL63 Hit #2 GTCFGTCW-NH2 S-S 871 464 
AJTL65 Hit #2 Ac-GTCFGTCW-NH2 S-S 914 30 
BR18 Hit #3 LVCKGYCQ-NH2 Linear 1026 ≥ 470 
BR19 Hit #3 Ac-LVCKGYCQ-NH2 Linear 1069 408 
AJTL48 Hit #3 LVCKGYCQ-NH2 S-S 1024 ≥ 470 
AJTL49 Hit #3 Ac-LVCKGYCQ-NH2 S-S 1067 427 
BR22 Hit #4 KVCMGGCT-NH2 Linear 796 361 
BR23 Hit #4 Ac-KVCMGGCT-NH2 Linear 839 ≥ 470 
AJTL69 Hit #4 KVCMGGCT-NH2 S-S 794 ≥ 470 
AJTL71 Hit #4 Ac-KVCMGGCT-NH2 S-S 837 459 
BR16 Hit #5 KWCAGMCV-NH2 Linear 1041 344 
BR17 Hit #5 Ac-KWCAGMCV-NH2 Linear 1082 223 
BR26 Hit #5 KWCAGMCV-NH2 S-S 1039 ≥ 470 
BR27 Hit #5 Ac-KWCAGMCV-NH2 S-S 1081 141 
AJTL68 Hit #6 FPCLGICY-NH2 Linear 914 431 
AJTL67 Hit #6 Ac-FPCLGICY-NH2 Linear 955 190 
AJTL97 Hit #6 FPCLGICY-NH2 S-S 912 ≥ 470 
AJTL89 Hit #6 Ac-FPCLGICY-NH2 S-S 954 63 
AJTL83 Hit #9 YWCKGLCK-NH2 Linear 1227 465 
AJTL82 Hit #9 Ac-YWCKGLCK-NH2 Linear 1268 460 
ALTJ93 Hit #9 YWCKGLCK-NH2 S-S 1225 463 
AJTL91 Hit #9 Ac-YWCKGLCK-NH2 S-S 1267 464 
BR32 Hit #9 YWCKGLCK-NH2 S-me-S 1354 ≥ 470 
AJTL85 Hit #10 SVCFGLCY-NH2 Linear 890 441 




AJTL99 Hit #10 SVCFGLCY-NH2 S-S 888 297 
AJT105 Hit #11 Ac-IKCRGICS-NH2 Linear 816 ND 
AJT115 Hit #11 Ac-IKCRGICS-NH2 S-S 814 ND 
AJT120 Hit #14 VFCAGACR-NH2 Linear 824 ND 
AJT119 Hit #14 Ac-VFCAGACR-NH2 Linear 866 ND 
AJT127 Hit #14 VFCAGACR-NH2 S-S 822 ND 
AJT125 Hit #14 Ac-VFCAGACR-NH2 S-S 864 ND 
BR30 Hit #16 KLCHGYCH-NH2 S-S 1186 400 
BR33 Hit #19 KHCYGFCY-NH2 Linear 1246 good 
BR34 Hit #19 Ac-KHCYGFCY-NH2 Linear 1289 good 
BR31 Hit #19 KHCYGFCY-NH2 S-S 1233 low 
BR35 Hit #19 Ac-KHCYGFCY-NH2 S-S 1287 421 
 
This table contains the names of peptides as they are referred to in laboratory 
notebooks. Solubility in pH 8.0 buffer was performed as described in Chapter 3 by 
myself (for “BR” peptides) or Anjanette Turbiak (for “AJ” pepides). FW masses include 
TFA salts. Please note that some of the “AJT” or “AJTL” peptides may also be referred 
to as “AJ” peptides. ND: Not determined. 
 
 
 
 
